Gene "Gene synonym" Ensembl "Gene description" Uniprot Chromosome Position "Protein class" "Biological process" "Molecular function" "Disease involvement" Evidence "HPA evidence" "UniProt evidence" "NeXtProt evidence" "MS evidence" "RNA tissue specificity" "RNA tissue distribution" "RNA tissue specificity score" "RNA tissue specific NX" "RNA cell line specificity" "RNA cell line distribution" "RNA cell line specificity score" "RNA cell line specific NX" "RNA cancer specificity" "RNA cancer distribution" "RNA cancer specificity score" "RNA cancer specific FPKM" "RNA brain regional specificity" "RNA brain regional distribution" "RNA brain regional specificity score" "RNA brain regional specific NX" "RNA blood cell specificity" "RNA blood cell distribution" "RNA blood cell specificity score" "RNA blood cell specific NX" "RNA blood lineage specificity" "RNA blood lineage distribution" "RNA blood lineage specificity score" "RNA blood lineage specific NX" "RNA mouse brain regional specificity" "RNA mouse brain regional distribution" "RNA mouse brain regional specificity score" "RNA mouse brain regional specific pTPM" "RNA pig brain regional specificity" "RNA pig brain regional distribution" "RNA pig brain regional specificity score" "RNA pig brain regional specific pTPM" Antibody "Reliability (IH)" "Reliability (Mouse Brain)" "Reliability (IF)" "Subcellular location" "Secretome location" "Blood concentration - Conc. blood IM [pg/L]" "Blood concentration - Conc. blood MS [pg/L]" "Subcellular main location" "Subcellular additional location" "Antibody RRID" "Pathology prognostics - Breast cancer" "Pathology prognostics - Cervical cancer" "Pathology prognostics - Colorectal cancer" "Pathology prognostics - Endometrial cancer" "Pathology prognostics - Glioma" "Pathology prognostics - Head and neck cancer" "Pathology prognostics - Liver cancer" "Pathology prognostics - Lung cancer" "Pathology prognostics - Melanoma" "Pathology prognostics - Ovarian cancer" "Pathology prognostics - Pancreatic cancer" "Pathology prognostics - Prostate cancer" "Pathology prognostics - Renal cancer" "Pathology prognostics - Stomach cancer" "Pathology prognostics - Testis cancer" "Pathology prognostics - Thyroid cancer" "Pathology prognostics - Urothelial cancer" "Tissue RNA - adipose tissue [NX]" "Tissue RNA - adrenal gland [NX]" "Tissue RNA - amygdala [NX]" "Tissue RNA - appendix [NX]" "Tissue RNA - basal ganglia [NX]" "Tissue RNA - bone marrow [NX]" "Tissue RNA - breast [NX]" "Tissue RNA - cerebellum [NX]" "Tissue RNA - cerebral cortex [NX]" "Tissue RNA - cervix, uterine [NX]" "Tissue RNA - colon [NX]" "Tissue RNA - corpus callosum [NX]" "Tissue RNA - ductus deferens [NX]" "Tissue RNA - duodenum [NX]" "Tissue RNA - endometrium 1 [NX]" "Tissue RNA - epididymis [NX]" "Tissue RNA - esophagus [NX]" "Tissue RNA - fallopian tube [NX]" "Tissue RNA - gallbladder [NX]" "Tissue RNA - heart muscle [NX]" "Tissue RNA - hippocampal formation [NX]" "Tissue RNA - hypothalamus [NX]" "Tissue RNA - kidney [NX]" "Tissue RNA - liver [NX]" "Tissue RNA - lung [NX]" "Tissue RNA - lymph node [NX]" "Tissue RNA - midbrain [NX]" "Tissue RNA - olfactory region [NX]" "Tissue RNA - ovary [NX]" "Tissue RNA - pancreas [NX]" "Tissue RNA - parathyroid gland [NX]" "Tissue RNA - pituitary gland [NX]" "Tissue RNA - placenta [NX]" "Tissue RNA - pons and medulla [NX]" "Tissue RNA - prostate [NX]" "Tissue RNA - rectum [NX]" "Tissue RNA - retina [NX]" "Tissue RNA - salivary gland [NX]" "Tissue RNA - seminal vesicle [NX]" "Tissue RNA - skeletal muscle [NX]" "Tissue RNA - skin 1 [NX]" "Tissue RNA - small intestine [NX]" "Tissue RNA - smooth muscle [NX]" "Tissue RNA - spinal cord [NX]" "Tissue RNA - spleen [NX]" "Tissue RNA - stomach 1 [NX]" "Tissue RNA - testis [NX]" "Tissue RNA - thalamus [NX]" "Tissue RNA - thymus [NX]" "Tissue RNA - thyroid gland [NX]" "Tissue RNA - tongue [NX]" "Tissue RNA - tonsil [NX]" "Tissue RNA - urinary bladder [NX]" "Tissue RNA - vagina [NX]" "Tissue RNA - B-cells [NX]" "Tissue RNA - dendritic cells [NX]" "Tissue RNA - granulocytes [NX]" "Tissue RNA - monocytes [NX]" "Tissue RNA - NK-cells [NX]" "Tissue RNA - T-cells [NX]" "Tissue RNA - total PBMC [NX]" "Cell RNA - A-431 [NX]" "Cell RNA - A549 [NX]" "Cell RNA - AF22 [NX]" "Cell RNA - AN3-CA [NX]" "Cell RNA - ASC diff [NX]" "Cell RNA - ASC TERT1 [NX]" "Cell RNA - BEWO [NX]" "Cell RNA - BJ [NX]" "Cell RNA - BJ hTERT+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ [NX]" "Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]" "Cell RNA - CACO-2 [NX]" "Cell RNA - CAPAN-2 [NX]" "Cell RNA - Daudi [NX]" "Cell RNA - EFO-21 [NX]" "Cell RNA - fHDF/TERT166 [NX]" "Cell RNA - HaCaT [NX]" "Cell RNA - HAP1 [NX]" "Cell RNA - HBEC3-KT [NX]" "Cell RNA - HBF TERT88 [NX]" "Cell RNA - HDLM-2 [NX]" "Cell RNA - HEK 293 [NX]" "Cell RNA - HEL [NX]" "Cell RNA - HeLa [NX]" "Cell RNA - Hep G2 [NX]" "Cell RNA - HHSteC [NX]" "Cell RNA - HL-60 [NX]" "Cell RNA - HMC-1 [NX]" "Cell RNA - HSkMC [NX]" "Cell RNA - hTCEpi [NX]" "Cell RNA - hTEC/SVTERT24-B [NX]" "Cell RNA - hTERT-HME1 [NX]" "Cell RNA - HUVEC TERT2 [NX]" "Cell RNA - K-562 [NX]" "Cell RNA - Karpas-707 [NX]" "Cell RNA - LHCN-M2 [NX]" "Cell RNA - MCF7 [NX]" "Cell RNA - MOLT-4 [NX]" "Cell RNA - NB-4 [NX]" "Cell RNA - NTERA-2 [NX]" "Cell RNA - PC-3 [NX]" "Cell RNA - REH [NX]" "Cell RNA - RH-30 [NX]" "Cell RNA - RPMI-8226 [NX]" "Cell RNA - RPTEC TERT1 [NX]" "Cell RNA - RT4 [NX]" "Cell RNA - SCLC-21H [NX]" "Cell RNA - SH-SY5Y [NX]" "Cell RNA - SiHa [NX]" "Cell RNA - SK-BR-3 [NX]" "Cell RNA - SK-MEL-30 [NX]" "Cell RNA - T-47d [NX]" "Cell RNA - THP-1 [NX]" "Cell RNA - TIME [NX]" "Cell RNA - U-138 MG [NX]" "Cell RNA - U-2 OS [NX]" "Cell RNA - U-2197 [NX]" "Cell RNA - U-251 MG [NX]" "Cell RNA - U-266/70 [NX]" "Cell RNA - U-266/84 [NX]" "Cell RNA - U-698 [NX]" "Cell RNA - U-87 MG [NX]" "Cell RNA - U-937 [NX]" "Cell RNA - WM-115 [NX]" "Blood RNA - basophil [NX]" "Blood RNA - classical monocyte [NX]" "Blood RNA - eosinophil [NX]" "Blood RNA - gdT-cell [NX]" "Blood RNA - intermediate monocyte [NX]" "Blood RNA - MAIT T-cell [NX]" "Blood RNA - memory B-cell [NX]" "Blood RNA - memory CD4 T-cell [NX]" "Blood RNA - memory CD8 T-cell [NX]" "Blood RNA - myeloid DC [NX]" "Blood RNA - naive B-cell [NX]" "Blood RNA - naive CD4 T-cell [NX]" "Blood RNA - naive CD8 T-cell [NX]" "Blood RNA - neutrophil [NX]" "Blood RNA - NK-cell [NX]" "Blood RNA - non-classical monocyte [NX]" "Blood RNA - plasmacytoid DC [NX]" "Blood RNA - T-reg [NX]" "Blood RNA - total PBMC [NX]" "Brain RNA - amygdala [NX]" "Brain RNA - basal ganglia [NX]" "Brain RNA - cerebellum [NX]" "Brain RNA - cerebral cortex [NX]" "Brain RNA - hippocampal formation [NX]" "Brain RNA - hypothalamus [NX]" "Brain RNA - midbrain [NX]" "Brain RNA - olfactory region [NX]" "Brain RNA - pons and medulla [NX]" "Brain RNA - thalamus [NX]" AR "AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1" ENSG00000169083 "Androgen receptor" P10275 X 67544032-67730619 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration, Pseudohermaphroditism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "liver: 49.0" "Cell line enhanced" "Detected in some" "AF22: 11.0;BJ hTERT+: 9.6;HAP1: 14.1;LHCN-M2: 12.4;RH-30: 20.5;T-47d: 8.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 16 "plasmacytoid DC: 5.4" "Lineage enriched" "Detected in single" 16 "dendritic cells: 5.4" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "CAB000001, HPA065701, CAB065764" Enhanced Approved Mitochondria Mitochondria "CAB000001: AB_2060174, CAB065764: AB_10620739, HPA065701: " "unprognostic (1.34e-1)" "unprognostic (8.10e-3)" "unprognostic (2.49e-2)" "unprognostic (5.95e-2)" "unprognostic (1.04e-2)" "unprognostic (3.35e-2)" "prognostic favourable (8.77e-4)" "unprognostic (4.99e-2)" "unprognostic (1.72e-1)" "unprognostic (7.79e-2)" "unprognostic (2.30e-1)" "unprognostic (2.29e-1)" "prognostic favourable (1.03e-8)" "unprognostic (8.23e-3)" "unprognostic (8.90e-2)" "unprognostic (4.23e-2)" "unprognostic (7.97e-2)" 10.1 1.2 0.9 1.6 0.9 0.1 10.7 0.4 1.6 34.4 1.9 2.4 25.4 0.2 20.5 20.5 2.2 17.5 4.3 5.7 0.9 1.5 6.3 49.0 1.5 0.2 1.2 0.7 14.4 1.0 0.1 2.3 0.3 1.9 28.0 0.5 3.8 1.6 36.1 8.1 3.9 1.1 7.6 1.9 0.9 1.6 9.3 1.2 5.4 3.1 2.0 1.2 6.3 13.1 0.0 5.4 0.3 0.0 0.1 0.0 0.1 0.0 4.6 11.0 0.0 0.0 0.1 0.0 5.8 9.6 0.4 0.1 0.2 0.0 0.0 0.0 0.7 0.0 14.1 0.0 0.1 0.0 1.8 0.0 1.1 0.0 0.6 0.0 0.0 4.5 0.0 1.6 0.0 3.4 4.0 1.8 12.4 1.2 0.0 0.0 4.4 0.0 0.0 20.5 0.0 0.3 0.0 0.0 0.0 0.0 0.2 0.0 8.6 5.2 0.2 0.2 2.0 0.1 2.9 0.0 0.0 0.0 4.2 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.3 0.1 0.0 5.4 0.0 0.1 0.9 0.9 0.4 1.6 0.9 1.5 1.2 0.7 1.9 1.2 DLGAP2 "C8orf68, DAP-2, ERICH1-AS1" ENSG00000198010 "DLG associated protein 2" Q9P1A6 8 737596-1708474 "Nuclear receptors, Predicted intracellular proteins" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 4 "brain: 15.3;testis: 12.5" "Group enriched" "Detected in some" 13 "NTERA-2: 2.0;REH: 3.3" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA030320 Uncertain "HPA030320: AB_10600904" "unprognostic (8.86e-2)" "unprognostic (2.32e-1)" "unprognostic (5.32e-1)" "unprognostic (1.33e-1)" "unprognostic (5.42e-2)" "unprognostic (1.23e-3)" "unprognostic (1.07e-1)" "unprognostic (2.71e-2)" "unprognostic (5.01e-2)" "unprognostic (2.16e-2)" "unprognostic (1.90e-3)" "unprognostic (2.53e-1)" "unprognostic (1.04e-1)" "unprognostic (2.05e-3)" "unprognostic (1.96e-1)" "unprognostic (3.85e-1)" "unprognostic (3.81e-1)" 0.8 1.0 7.5 0.8 14.9 0.9 0.8 0.4 15.3 1.3 0.7 0.0 0.3 0.7 0.7 1.5 0.7 0.7 0.6 0.7 8.0 3.1 2.0 0.8 0.7 0.9 1.1 8.9 0.7 0.6 0.6 3.4 0.8 0.7 0.8 0.6 0.0 0.8 0.9 0.6 1.5 0.7 0.7 0.6 0.9 0.6 12.5 1.2 0.0 1.6 0.0 0.8 0.7 0.1 0.0 0.0 0.4 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 2.0 0.0 3.3 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 7.5 14.9 0.4 15.3 8.0 3.1 1.1 8.9 0.7 1.2 ESR1 "ER-alpha, Era, ESR, NR3A1" ENSG00000091831 "Estrogen receptor 1" P03372 6 151656691-152129619 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "cervix, uterine: 64.5;endometrium 1: 68.9" "Group enriched" "Detected in some" 9 "MCF7: 24.3;T-47d: 31.5" "Group enriched" "Detected in many" 9 "breast cancer: 40.2;endometrial cancer: 24.3;ovarian cancer: 8.7" "Not detected" "Not detected" "Cell type enhanced" "Detected in some" "naive CD4 T-cell: 2.5" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in single" "Low region specificity" "Detected in many" "CAB000037, HPA000449, HPA000450, CAB055099, CAB072858" Enhanced Approved Nucleoplasm,Vesicles Vesicles Nucleoplasm "CAB000037: AB_563706, CAB055099: AB_2101946, CAB072858: , HPA000449: AB_1078753, HPA000450: AB_1078754" "unprognostic (8.28e-2)" "unprognostic (3.02e-2)" "unprognostic (1.43e-2)" "prognostic favourable (5.47e-7)" "unprognostic (4.79e-1)" "unprognostic (2.43e-3)" "unprognostic (4.10e-5)" "unprognostic (9.92e-2)" "unprognostic (2.20e-1)" "unprognostic (7.17e-2)" "unprognostic (7.35e-2)" "unprognostic (3.45e-1)" "unprognostic (1.20e-2)" "unprognostic (7.91e-3)" "unprognostic (6.45e-2)" "unprognostic (1.25e-1)" "unprognostic (1.52e-1)" 3.0 0.9 0.5 1.6 0.5 0.2 16.2 0.8 0.4 64.5 1.5 0.2 2.2 0.1 68.9 27.7 1.1 26.7 1.9 1.1 0.5 0.8 1.5 6.6 3.6 1.6 0.4 0.1 14.2 0.4 0.0 9.3 0.9 0.6 3.6 0.1 2.6 1.6 4.1 2.0 0.6 0.5 20.8 0.4 1.6 0.3 1.9 0.4 1.9 1.3 2.2 2.5 3.8 23.7 0.6 1.0 0.0 0.8 0.3 2.5 1.0 0.3 0.0 0.1 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.2 0.1 0.1 0.0 0.0 0.6 0.0 24.3 0.0 0.0 0.0 0.0 0.7 0.0 0.4 0.0 1.8 0.0 0.0 0.0 0.3 0.0 31.5 0.0 0.0 0.1 0.1 0.3 0.0 2.9 0.5 0.0 0.1 0.2 0.0 0.0 0.8 0.0 0.3 0.2 1.0 0.6 1.3 0.4 1.0 0.4 2.5 0.9 0.0 0.3 0.0 0.0 0.3 1.0 0.5 0.5 0.8 0.4 0.5 0.8 0.4 0.1 0.6 0.4 ESR2 "ER-beta, Erb, NR3A2" ENSG00000140009 "Estrogen receptor 2" Q92731 14 64084232-64338112 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "ovary: 19.1;testis: 30.2;vagina: 14.3" "Cell line enhanced" "Detected in some" "U-266/70: 10.5;U-698: 17.2" "Not detected" "Not detected" "Low region specificity" "Detected in some" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in some" "Region enriched" "Detected in many" 5 "cerebellum: 17.8" CAB079300 Enhanced "CAB079300: " "unprognostic (7.63e-3)" "unprognostic (2.28e-3)" "unprognostic (8.27e-3)" "unprognostic (5.41e-2)" "unprognostic (2.91e-2)" "unprognostic (1.06e-1)" "unprognostic (1.80e-1)" "unprognostic (4.38e-2)" "unprognostic (1.95e-1)" "unprognostic (8.75e-2)" "unprognostic (2.57e-2)" "unprognostic (1.65e-1)" "unprognostic (3.03e-5)" "unprognostic (1.57e-1)" "unprognostic (1.66e-1)" "unprognostic (4.21e-2)" "unprognostic (5.89e-2)" 2.1 9.4 0.2 2.3 0.8 1.0 3.7 0.8 0.6 1.3 2.9 0.6 0.2 1.4 1.7 0.7 1.7 1.1 0.6 1.0 1.1 0.4 1.4 0.7 1.3 2.8 0.2 0.2 19.1 2.5 0.0 1.6 0.7 1.4 2.2 1.5 0.5 1.5 0.9 1.4 1.2 1.5 0.6 1.0 3.0 1.3 30.2 0.6 5.0 0.6 0.2 2.9 1.8 14.3 2.4 4.0 1.1 0.3 0.4 1.3 0.2 0.7 0.3 0.7 0.6 0.0 0.1 1.3 0.1 0.0 0.1 0.1 0.2 0.8 2.8 0.1 0.0 1.0 0.9 0.0 0.1 0.7 0.3 0.3 0.7 0.1 0.1 0.1 0.2 0.0 0.0 0.1 0.2 0.2 0.6 4.0 0.1 0.7 0.4 0.2 0.7 0.4 0.5 0.3 0.2 0.1 1.3 2.4 0.7 0.5 0.2 1.1 0.8 0.0 0.4 0.5 0.9 0.2 0.1 10.5 3.2 17.2 0.2 0.1 0.7 0.3 0.3 1.0 0.8 0.2 0.6 1.7 0.6 1.1 0.1 2.4 1.3 1.0 1.1 0.4 0.2 4.0 0.5 0.2 0.2 0.8 0.8 0.6 1.1 0.4 0.2 0.2 1.4 0.6 ESRRA "ERR1, ERRa, ERRalpha, ESRL1, NR3B1" ENSG00000173153 "Estrogen related receptor alpha" P11474 11 64305572-64316743 "Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skeletal muscle: 78.3" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA053785 Supported "Nucleoplasm,Nucleoli fibrillar center,Microtubules,Cytokinetic bridge" "Nucleoplasm, Nucleoli fibrillar center, Microtubules" "Cytokinetic bridge" "HPA053785: " "unprognostic (7.63e-2)" "unprognostic (1.51e-1)" "unprognostic (1.04e-1)" "unprognostic (1.28e-2)" "unprognostic (3.08e-1)" "unprognostic (7.24e-2)" "unprognostic (1.07e-1)" "unprognostic (2.97e-1)" "unprognostic (2.98e-1)" "unprognostic (3.52e-2)" "unprognostic (2.50e-2)" "unprognostic (1.03e-1)" "prognostic favourable (1.34e-7)" "unprognostic (3.43e-3)" "unprognostic (3.19e-2)" "unprognostic (2.38e-2)" "unprognostic (7.20e-2)" 8.2 9.6 6.0 8.9 7.7 7.9 17.8 9.8 9.4 4.3 32.4 4.9 18.3 43.1 4.6 6.2 17.1 4.1 15.7 45.2 6.8 5.0 21.4 26.9 8.7 9.2 10.4 5.2 2.5 20.5 10.1 4.6 11.0 8.0 7.5 12.6 6.0 28.7 14.9 78.3 10.5 46.4 7.1 7.4 9.3 14.1 2.2 6.0 6.0 8.2 27.1 10.0 8.5 12.0 4.1 4.2 8.5 8.4 2.6 5.4 2.4 9.7 15.6 3.9 9.4 5.3 5.1 21.2 9.6 4.7 3.6 3.6 14.4 11.9 13.4 18.0 5.1 25.1 6.5 12.9 1.4 9.0 8.4 8.6 18.5 11.3 7.3 14.6 21.8 7.2 19.7 8.1 10.7 5.0 14.5 7.4 5.9 21.9 7.1 20.8 10.8 29.7 7.7 7.6 29.9 12.0 20.6 8.2 10.1 4.9 32.7 30.9 10.1 14.5 10.8 6.6 7.9 18.5 9.7 11.4 9.4 8.8 10.7 14.4 5.2 0.3 4.7 7.1 4.4 8.4 4.4 2.9 3.8 3.1 4.2 4.1 4.1 5.4 8.5 2.6 7.5 3.2 5.1 2.4 6.0 7.7 9.8 9.4 6.8 5.0 10.4 5.2 8.0 6.0 ESRRG NR3B3 ENSG00000196482 "Estrogen related receptor gamma" P62508 1 216503246-217137755 "FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 49.5;parathyroid gland: 37.2;placenta: 40.8" "Group enriched" "Detected in some" 4 "RPMI-8226: 15.1;SH-SY5Y: 28.8" "Low cancer specificity" "Detected in many" "Region enriched" "Detected in all" 5 "pons and medulla: 49.5" "Cell type enhanced" "Detected in single" "neutrophil: 1.5" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA044678 Uncertain Approved Nucleoplasm Nucleoplasm "HPA044678: AB_10963215" "unprognostic (6.48e-2)" "unprognostic (1.11e-1)" "unprognostic (7.06e-2)" "unprognostic (7.32e-2)" "unprognostic (2.34e-1)" "unprognostic (5.48e-2)" "unprognostic (1.66e-1)" "unprognostic (1.13e-1)" "unprognostic (4.55e-2)" "unprognostic (2.88e-1)" "unprognostic (2.35e-1)" "unprognostic (1.79e-2)" "prognostic favourable (1.13e-11)" "unprognostic (3.04e-1)" "unprognostic (2.55e-1)" "unprognostic (3.65e-4)" "unprognostic (2.05e-1)" 0.5 5.1 2.8 0.4 3.3 0.2 2.9 6.9 10.3 1.4 0.7 0.7 2.2 4.0 0.5 1.5 1.4 2.1 0.8 8.3 3.2 2.6 22.0 0.8 0.7 0.4 6.8 1.7 0.8 4.4 37.2 9.9 40.8 49.5 2.6 0.4 10.7 11.0 2.4 6.3 1.5 3.7 0.9 2.6 1.0 22.2 1.0 1.5 0.0 4.6 7.2 0.4 1.0 0.7 0.4 0.2 1.5 0.0 0.2 0.1 0.0 0.2 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.8 0.1 0.0 0.0 0.0 0.0 2.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.1 0.0 0.0 15.1 2.3 1.7 5.4 28.8 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.1 0.3 0.0 0.0 0.1 0.0 0.1 0.1 0.1 0.0 0.0 0.4 0.1 0.1 1.5 0.2 0.0 0.2 0.0 0.0 2.8 3.3 6.9 10.3 3.2 2.6 6.8 1.7 49.5 1.5 HNF4A "HNF4, MODY, MODY1, NR2A1, TCF14" ENSG00000101076 "Hepatocyte nuclear factor 4 alpha" P41235 20 44355700-44434596 "Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor, Repressor" "Diabetes mellitus, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in some" "intestine: 65.5;kidney: 30.5;liver: 57.3" "Group enriched" "Detected in some" 9 "CACO-2: 51.6;Hep G2: 37.9" "Cancer enhanced" "Detected in many" "colorectal cancer: 48.2" "Not detected" "Not detected" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Not detected" "Not detected" "Not detected" "Not detected" "HPA004712, CAB019417" Enhanced Supported Nucleoplasm Nucleoplasm "CAB019417: AB_2295208, HPA004712: AB_1079075" "unprognostic (2.47e-1)" "unprognostic (3.08e-1)" "unprognostic (2.34e-1)" "unprognostic (2.29e-1)" "unprognostic (8.54e-2)" "unprognostic (1.56e-2)" "unprognostic (6.90e-2)" "unprognostic (4.79e-3)" "unprognostic (2.59e-2)" "unprognostic (3.77e-2)" "unprognostic (2.45e-2)" "unprognostic (1.05e-1)" "unprognostic (2.75e-2)" "unprognostic (8.40e-3)" "unprognostic (2.12e-1)" "unprognostic (2.70e-2)" 0.2 0.2 0.2 13.4 0.2 0.0 0.2 0.2 0.3 0.2 54.0 0.2 0.1 33.0 0.2 6.2 0.2 0.4 15.7 0.2 0.2 0.2 30.5 57.3 0.3 0.1 0.2 0.1 0.3 22.7 0.0 0.2 0.1 0.2 0.2 14.4 0.2 0.2 0.1 0.2 0.2 65.5 0.3 0.2 0.2 7.1 0.4 0.1 0.1 0.2 0.1 0.1 0.2 0.4 0.4 0.6 1.2 0.8 0.8 0.4 0.0 0.0 4.9 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 51.6 2.0 0.0 0.3 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.2 37.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.2 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.1 0.4 0.4 0.4 0.7 0.8 0.8 0.6 0.3 0.0 0.2 0.2 0.2 0.3 0.2 0.2 0.2 0.1 0.2 0.1 HNF4G NR2A2 ENSG00000164749 "Hepatocyte nuclear factor 4 gamma" Q14541 8 75407914-75566843 "Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 11 "intestine: 139.6" "Cell line enhanced" "Detected in some" "A549: 4.6;CAPAN-2: 17.3;Karpas-707: 4.9;PC-3: 5.3;THP-1: 5.8" "Low cancer specificity" "Detected in many" "Not detected" "Not detected" "Cell type enriched" "Detected in single" 13 "gdT-cell: 1.3" "Lineage enriched" "Detected in single" 13 "T-cells: 1.3" "Not detected" "Not detected" "Not detected" "Not detected" "HPA005438, HPA010610" Enhanced Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA005438: AB_1850822, HPA010610: " "unprognostic (2.09e-1)" "unprognostic (2.90e-1)" "unprognostic (1.77e-2)" "unprognostic (9.44e-2)" "unprognostic (5.60e-2)" "unprognostic (4.65e-2)" "unprognostic (5.26e-2)" "unprognostic (1.27e-2)" "unprognostic (3.92e-1)" "unprognostic (8.09e-2)" "unprognostic (3.68e-2)" "unprognostic (1.83e-2)" "unprognostic (6.93e-3)" "unprognostic (1.67e-2)" "unprognostic (2.11e-1)" "unprognostic (4.22e-2)" "unprognostic (2.47e-2)" 0.2 0.2 0.5 5.0 0.5 0.0 0.3 0.3 0.3 0.6 56.2 0.1 0.3 35.9 0.4 1.1 0.4 0.3 12.6 0.2 0.3 0.3 6.1 12.1 0.4 0.0 0.4 0.2 0.2 10.9 0.0 0.2 0.0 0.3 0.6 6.9 0.2 0.4 0.6 0.2 0.2 139.6 0.2 0.3 0.2 2.6 0.9 0.1 0.1 0.2 0.0 0.0 0.5 0.3 0.0 0.0 0.0 0.0 0.0 1.3 0.0 1.1 4.6 0.2 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.4 0.3 17.3 0.0 2.5 0.0 0.0 2.2 0.0 0.0 0.0 1.9 0.0 0.0 3.0 0.0 0.0 0.0 0.1 0.2 0.0 0.1 0.0 0.0 4.9 0.0 0.0 0.0 0.3 0.3 5.3 0.0 0.0 0.3 3.0 0.1 0.3 1.7 0.4 0.1 0.0 0.3 5.8 0.0 0.4 0.2 0.1 0.0 1.2 0.0 0.0 0.4 0.0 0.8 0.0 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.5 0.3 0.3 0.3 0.3 0.4 0.2 0.3 0.1 NR0B1 "AHC, AHCH, DAX1, DSS" ENSG00000169297 "Nuclear receptor subfamily 0 group B member 1" P51843 X 30304206-30309598 "Cancer-related genes, Disease related genes, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Receptor, Repressor" "Cancer-related genes, Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 8 "adrenal gland: 23.9;testis: 36.0" "Group enriched" "Detected in some" 4 "A549: 34.3;RT4: 10.8" "Cancer enhanced" "Detected in many" "lung cancer: 4.1" "Low region specificity" "Detected in some" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in some" "HPA061948, HPA067207" Supported "Nuclear speckles,Vesicles,Centriolar satellite" "Nuclear speckles" "Vesicles, Centriolar satellite" "HPA061948: , HPA067207: " "unprognostic (1.50e-2)" "unprognostic (9.68e-2)" "unprognostic (9.47e-3)" "unprognostic (1.23e-1)" "unprognostic (2.81e-1)" "unprognostic (7.45e-3)" "unprognostic (4.83e-2)" "unprognostic (9.00e-2)" "unprognostic (1.33e-3)" 0.4 23.9 1.0 0.0 0.8 0.0 0.2 0.4 1.1 1.3 0.1 1.7 0.0 0.0 0.4 0.9 0.1 0.0 0.0 0.0 0.9 0.9 0.0 0.0 0.1 0.0 0.5 0.6 3.5 2.1 0.0 1.6 0.0 0.6 0.2 0.1 0.0 0.0 0.0 0.0 0.2 0.1 0.7 0.6 0.1 0.7 36.0 0.7 0.1 0.0 0.0 0.1 0.0 1.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 34.3 0.0 0.0 1.3 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 3.9 0.0 1.3 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 0.0 10.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.0 0.0 0.0 0.0 5.0 0.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.8 0.4 1.1 0.9 0.9 0.5 0.6 0.6 0.7 NR1D1 "ear-1, hRev, Rev-ErbAalpha, THRA1, THRAL" ENSG00000126368 "Nuclear receptor subfamily 1 group D member 1" P20393 17 40092787-40100725 "Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Differentiation, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor, Repressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "Karpas-707: 32.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 16.3" "Group enriched" "Detected in many" 6 "monocytes: 4.2;T-cells: 16.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA007935 Uncertain Supported "Nuclear bodies" "Nuclear bodies" "HPA007935: AB_10601277" "unprognostic (1.38e-2)" "unprognostic (3.46e-2)" "prognostic unfavourable (1.94e-4)" "unprognostic (2.53e-1)" "unprognostic (2.24e-2)" "unprognostic (1.05e-1)" "unprognostic (4.50e-2)" "unprognostic (1.03e-1)" "prognostic favourable (1.36e-4)" "unprognostic (1.93e-3)" "unprognostic (9.93e-3)" "unprognostic (2.73e-1)" "unprognostic (9.15e-3)" "unprognostic (4.54e-3)" "unprognostic (2.49e-1)" "unprognostic (3.09e-1)" "unprognostic (1.34e-1)" 19.4 15.1 12.2 7.6 14.7 6.0 30.5 30.7 32.5 45.9 13.9 6.4 17.3 15.2 16.5 6.1 16.8 10.7 8.2 43.7 8.8 5.2 9.8 14.8 12.7 8.8 4.7 11.7 33.3 8.3 4.8 10.9 7.3 6.1 15.5 5.5 28.0 53.0 18.6 51.2 79.3 8.8 27.3 6.0 7.8 7.9 7.3 6.8 1.8 13.9 11.7 10.6 28.0 25.4 1.8 1.1 0.1 4.2 0.8 16.3 1.5 2.8 4.1 0.8 3.3 4.9 3.4 1.2 6.3 10.3 2.1 2.6 2.7 10.3 3.4 3.8 7.2 8.1 2.2 9.4 1.5 2.9 2.3 2.5 4.1 6.9 8.0 3.7 3.7 7.4 6.8 7.1 15.2 2.6 3.7 32.2 2.0 2.0 5.5 3.3 1.6 6.5 3.9 1.3 10.6 2.8 2.6 2.8 1.6 3.9 5.2 6.4 2.5 3.1 2.5 9.3 9.2 7.6 4.9 11.7 17.8 1.4 12.6 2.1 7.1 0.0 0.4 0.0 3.9 1.6 16.3 1.5 4.9 5.7 0.9 1.8 4.5 3.2 0.1 0.8 4.2 1.1 6.5 1.5 12.2 14.7 30.7 32.5 8.8 5.2 4.7 11.7 6.1 6.8 NR1D2 "BD73, EAR-1r, Hs.37288, HZF2, RVR" ENSG00000174738 "Nuclear receptor subfamily 1 group D member 2" Q14995 3 23945260-23980618 "Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor, Repressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA053868, HPA054798" Approved Approved Nucleoplasm Nucleoplasm "HPA053868: , HPA054798: AB_2616453" "unprognostic (8.64e-2)" "unprognostic (9.96e-3)" "unprognostic (2.27e-1)" "unprognostic (2.46e-1)" "unprognostic (8.67e-2)" "unprognostic (2.09e-2)" "unprognostic (2.04e-1)" "unprognostic (3.61e-2)" "unprognostic (2.60e-1)" "unprognostic (6.79e-3)" "unprognostic (2.21e-1)" "unprognostic (5.73e-2)" "prognostic favourable (4.47e-7)" "unprognostic (2.36e-3)" "unprognostic (1.23e-1)" "unprognostic (1.08e-1)" "unprognostic (1.59e-1)" 15.2 12.5 15.2 7.9 17.1 9.5 15.9 40.9 31.9 21.1 13.3 14.0 20.9 10.0 19.0 11.0 12.2 13.3 11.0 22.5 15.0 13.4 16.8 22.1 10.6 9.6 14.4 16.1 24.3 12.7 41.6 15.8 10.0 16.1 15.1 9.0 16.3 22.2 23.1 35.4 14.2 10.4 15.6 14.6 13.1 10.9 5.6 15.1 5.5 40.7 23.2 10.5 13.0 14.3 2.4 0.9 0.2 2.5 1.1 6.1 1.0 9.7 2.2 5.2 4.9 5.5 5.9 3.2 14.6 19.2 8.1 9.1 1.6 9.7 7.0 4.9 20.4 6.6 6.5 9.5 17.0 2.5 7.6 1.1 5.2 1.9 11.5 3.7 1.0 7.8 10.1 9.9 25.5 5.5 2.5 25.5 6.4 5.6 2.0 1.2 5.6 11.2 1.8 8.4 4.7 4.5 13.5 5.4 12.0 10.6 6.1 12.6 5.4 3.2 10.9 21.3 21.7 13.7 16.6 12.5 16.8 3.3 12.1 5.6 12.3 0.0 0.8 0.1 3.3 2.5 6.1 2.4 3.7 3.1 0.9 1.9 2.6 2.6 0.2 1.1 1.4 0.9 2.2 1.0 15.2 17.1 40.9 31.9 15.0 13.4 14.4 16.1 16.1 15.1 NR1H2 "LXR-b, NER, NER-I, RIP15, UNR" ENSG00000131408 "Nuclear receptor subfamily 1 group H member 2" P55055 19 50329653-50382982 "Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA005446, HPA056838, HPA070212" Uncertain Enhanced Nucleoplasm,Vesicles Nucleoplasm Vesicles "HPA005446: , HPA056838: , HPA070212: " "unprognostic (1.31e-1)" "unprognostic (5.35e-2)" "prognostic unfavourable (9.86e-4)" "unprognostic (1.34e-3)" "unprognostic (1.68e-1)" "unprognostic (5.24e-3)" "unprognostic (2.26e-2)" "unprognostic (9.69e-2)" "unprognostic (6.45e-2)" "unprognostic (5.23e-2)" "unprognostic (2.40e-1)" "unprognostic (1.88e-1)" "unprognostic (2.69e-2)" "unprognostic (1.86e-1)" "unprognostic (1.35e-1)" "unprognostic (5.12e-2)" "unprognostic (1.69e-3)" 30.1 27.5 24.5 24.7 27.5 98.0 24.4 20.6 33.5 25.1 30.9 23.1 25.2 30.9 31.2 23.1 27.9 26.9 28.7 36.8 23.8 19.4 27.1 31.4 28.3 23.3 31.7 25.9 26.5 37.6 22.0 18.6 30.5 28.1 27.9 10.5 23.2 33.8 33.8 76.2 25.3 30.3 29.9 22.9 29.9 26.7 21.2 29.1 20.4 27.1 24.4 21.7 33.2 27.6 34.1 34.2 63.0 37.7 22.3 28.6 32.5 16.0 42.2 4.1 10.3 12.1 12.8 13.2 22.2 18.9 13.2 15.1 8.7 15.6 10.3 19.9 13.3 15.0 2.6 12.1 3.2 25.7 22.7 9.9 14.2 9.0 23.3 16.3 27.1 13.4 16.6 13.5 9.2 12.0 16.1 21.5 7.4 17.8 11.6 13.4 8.3 36.3 7.0 10.7 17.9 11.3 18.0 4.6 16.1 14.4 17.9 13.9 12.3 13.6 15.1 17.7 14.4 18.0 19.7 26.9 22.2 7.5 35.3 10.8 17.7 39.1 35.9 63.0 27.7 35.0 27.0 34.1 27.4 25.9 34.2 34.1 28.6 24.9 55.4 22.3 37.7 29.5 24.4 32.5 24.5 27.5 20.6 33.5 23.8 19.4 31.7 25.9 28.1 29.1 NR1H3 "LXR-a, RLD-1" ENSG00000025434 "Nuclear receptor subfamily 1 group H member 3" Q13133 11 47248300-47269032 "Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "adipose tissue: 74.2" "Cell line enhanced" "Detected in many" "ASC TERT1: 22.5;HSkMC: 29.3" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "intermediate monocyte: 14.6" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA036443, CAB037109" Approved "CAB037109: AB_1840991, HPA036443: AB_10966142" "unprognostic (2.95e-3)" "unprognostic (5.31e-3)" "unprognostic (5.19e-2)" "prognostic favourable (5.05e-4)" "unprognostic (1.19e-1)" "unprognostic (2.65e-2)" "prognostic unfavourable (5.60e-4)" "unprognostic (1.51e-1)" "unprognostic (1.76e-1)" "unprognostic (7.73e-2)" "unprognostic (2.08e-1)" "unprognostic (1.03e-1)" "prognostic unfavourable (1.40e-5)" "unprognostic (3.56e-1)" "unprognostic (4.42e-2)" "unprognostic (2.84e-1)" "prognostic favourable (3.40e-4)" 74.2 9.4 4.8 12.7 6.9 1.2 22.8 7.0 5.5 10.2 17.9 4.4 7.2 23.1 6.7 10.0 6.6 8.1 9.2 8.5 4.0 2.9 10.3 35.7 13.7 29.4 6.8 5.6 7.5 7.8 4.3 3.5 16.1 4.3 10.1 5.9 6.4 7.1 9.0 6.1 5.1 19.0 7.1 3.4 40.2 7.6 13.7 4.1 6.3 9.7 2.6 10.7 10.8 12.9 1.1 4.5 6.5 14.6 6.1 3.8 2.1 1.5 6.6 3.0 2.9 20.5 22.5 14.4 1.7 8.4 2.7 4.3 8.2 21.0 2.9 3.2 1.3 4.4 3.6 2.9 1.9 2.7 2.9 3.8 8.9 12.2 8.4 1.4 0.5 29.3 1.8 4.3 2.5 2.4 4.7 1.2 1.9 6.9 2.6 7.7 3.3 2.2 3.9 4.1 1.9 2.5 15.0 3.0 1.0 5.9 3.9 5.0 9.5 3.7 0.6 2.2 3.0 4.4 0.9 5.8 8.5 3.5 4.1 1.8 1.0 6.5 2.9 2.4 1.5 14.6 2.1 1.1 1.7 1.4 4.5 0.9 1.8 1.5 1.5 6.1 4.5 0.8 3.8 2.1 4.8 6.9 7.0 5.5 4.0 2.9 6.8 5.6 4.3 4.1 NR1H4 "FXR, HRR-1, HRR1, RIP14" ENSG00000012504 "Nuclear receptor subfamily 1 group H member 4" Q96RI1 12 100473708-100564413 "Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters" "Immunity, Inflammatory response, Innate immunity, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor, Repressor" "Disease mutation, FDA approved drug targets, Intrahepatic cholestasis" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 4 "liver: 109.4" "Group enriched" "Detected in some" 32 "Hep G2: 17.9;HHSteC: 10.8;RPTEC TERT1: 29.0" "Group enriched" "Detected in some" 11 "liver cancer: 18.7;renal cancer: 12.6" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" HPA047699 Approved Nucleoplasm Nucleoplasm "HPA047699: AB_10965320" "unprognostic (1.78e-1)" "unprognostic (1.81e-1)" "unprognostic (6.68e-2)" "unprognostic (2.49e-1)" "unprognostic (1.60e-1)" "unprognostic (9.39e-2)" "unprognostic (2.01e-1)" "unprognostic (1.88e-2)" "unprognostic (1.16e-1)" "unprognostic (2.43e-1)" "unprognostic (3.77e-3)" 0.1 11.3 0.1 1.4 0.4 0.0 0.2 0.1 0.2 0.2 5.8 0.4 0.1 11.3 0.1 0.4 0.1 0.1 7.0 0.1 0.1 0.0 25.0 109.4 0.6 2.4 0.1 0.1 7.7 2.7 0.0 2.9 0.2 0.3 0.5 0.4 0.6 0.1 0.1 0.1 0.0 19.5 0.3 0.1 0.2 0.1 0.2 0.1 0.1 0.1 0.3 0.3 1.7 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.9 10.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 29.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.1 0.2 0.1 0.0 0.1 0.1 0.3 0.1 NR1I2 "BXR, ONR1, PAR2, PXR, SXR" ENSG00000144852 "Nuclear receptor subfamily 1 group I member 2" O75469 3 119780484-119818485 "FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in some" 7 "blood: 7.1;intestine: 15.4;liver: 22.2" "Cell line enriched" "Detected in some" 4 "Hep G2: 17.3" "Group enriched" "Detected in some" 24 "colorectal cancer: 9.0;liver cancer: 5.7;pancreatic cancer: 2.6;stomach cancer: 2.7" "Cell type enriched" "Detected in single" 18 "NK-cell: 7.1" "Lineage enriched" "Detected in single" 18 "NK-cells: 7.1" "Not detected" "Not detected" "Low region specificity" "Detected in all" "HPA029309, HPA055121, HPA073926" Enhanced Nucleoplasm Nucleoplasm "HPA029309: , HPA055121: , HPA073926: " "unprognostic (6.76e-3)" "unprognostic (2.25e-1)" "unprognostic (5.84e-2)" "unprognostic (1.24e-4)" "unprognostic (4.51e-2)" "unprognostic (4.52e-2)" "unprognostic (4.03e-3)" "unprognostic (3.97e-2)" "unprognostic (5.78e-2)" "unprognostic (5.05e-2)" "unprognostic (5.21e-2)" "unprognostic (3.60e-2)" "unprognostic (5.51e-6)" "unprognostic (4.86e-1)" "unprognostic (6.95e-2)" "unprognostic (3.13e-1)" "unprognostic (6.12e-3)" 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 0.0 5.6 15.4 0.0 0.0 0.0 0.0 2.0 0.0 0.0 0.3 0.0 22.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 5.5 0.0 0.0 0.0 0.0 15.1 0.0 0.0 0.1 0.7 0.0 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 7.1 0.3 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 17.3 0.1 0.6 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.2 0.0 0.0 0.0 4.3 0.0 0.0 0.0 0.0 0.2 0.1 0.0 0.0 0.0 1.6 0.5 0.0 0.0 0.0 0.0 0.4 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.3 0.1 0.1 0.0 0.0 0.0 0.0 0.0 7.1 0.0 0.0 0.3 0.1 NR1I3 "CAR, CAR1, MB67" ENSG00000143257 "Nuclear receptor subfamily 1 group I member 3" Q14994 1 161229666-161238302 "Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 18 "liver: 63.1" "Cell line enhanced" "Detected in many" "CACO-2: 9.2" "Cancer enriched" "Detected in single" 67 "liver cancer: 17.6" "Region enriched" "Detected in single" 6 "basal ganglia: 1.9" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" HPA051365 Approved Nucleoplasm Nucleoplasm "HPA051365: AB_2616454" "unprognostic (2.59e-3)" "unprognostic (1.06e-2)" "unprognostic (9.33e-2)" "unprognostic (6.92e-4)" "unprognostic (2.55e-1)" "unprognostic (1.88e-2)" "unprognostic (1.91e-2)" "unprognostic (5.51e-2)" "unprognostic (8.69e-2)" "unprognostic (1.85e-1)" "unprognostic (6.23e-2)" "unprognostic (5.63e-3)" "unprognostic (2.71e-1)" "unprognostic (5.79e-2)" "unprognostic (6.44e-2)" "unprognostic (5.48e-3)" "unprognostic (2.62e-2)" 0.1 0.0 0.2 0.1 1.9 0.1 0.1 0.1 0.2 0.1 0.7 0.1 0.1 0.9 0.1 0.1 0.1 0.0 0.1 0.1 0.2 0.1 3.5 63.1 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.5 0.1 0.1 0.1 0.0 0.1 0.1 0.1 0.5 0.3 2.3 0.1 0.1 0.1 0.0 0.2 0.3 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.7 0.3 0.0 0.6 0.3 0.3 0.9 1.1 0.6 0.0 0.0 0.9 0.3 0.0 0.0 0.0 9.2 0.3 1.0 0.6 0.0 0.6 0.0 0.0 0.0 1.0 0.9 0.0 0.1 2.2 0.0 1.7 1.6 0.0 0.0 0.0 0.0 0.0 1.1 0.4 0.0 0.8 0.3 0.6 1.7 1.2 0.9 0.8 0.5 0.0 1.8 2.2 1.4 0.3 2.9 0.4 2.0 1.1 2.2 0.6 0.7 1.4 0.2 1.4 2.1 1.2 0.5 2.8 0.5 0.7 0.2 0.0 0.6 0.3 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.4 0.0 0.0 0.0 0.2 0.0 0.3 0.2 1.9 0.1 0.2 0.2 0.1 0.1 0.1 0.1 0.3 NR2C1 "TR2, TR2-11" ENSG00000120798 "Nuclear receptor subfamily 2 group C member 1" P13056 12 95020229-95073703 "Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor, Repressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA035040, HPA035041, HPA067767" Supported Supported "Nucleoplasm,Cell Junctions,Cytosol" Nucleoplasm "Cell Junctions, Cytosol" "HPA035040: , HPA035041: , HPA067767: " "unprognostic (2.44e-1)" "unprognostic (8.04e-3)" "unprognostic (3.17e-2)" "unprognostic (2.51e-1)" "unprognostic (3.56e-3)" "unprognostic (3.01e-2)" "prognostic unfavourable (5.18e-5)" "unprognostic (1.30e-2)" "unprognostic (1.29e-2)" "unprognostic (1.86e-1)" "unprognostic (3.83e-2)" "unprognostic (4.56e-2)" "prognostic unfavourable (1.03e-6)" "unprognostic (2.31e-1)" "unprognostic (1.42e-1)" "unprognostic (2.16e-1)" "prognostic favourable (5.62e-5)" 11.6 15.8 15.9 11.8 14.7 15.5 12.4 38.3 23.9 12.5 11.2 12.5 12.9 11.2 17.6 20.2 8.3 15.5 11.1 14.8 14.6 9.3 10.3 14.0 14.2 9.9 11.7 15.2 16.3 12.5 16.4 15.4 11.2 13.7 10.7 12.7 14.6 8.0 17.4 19.6 11.0 11.2 15.7 14.2 14.3 10.5 22.2 14.9 12.3 18.0 9.0 10.2 12.3 10.7 4.5 6.2 3.5 4.2 3.5 9.0 3.9 8.0 10.0 15.9 7.4 3.7 6.6 22.6 7.9 5.7 7.9 7.4 8.8 4.5 9.7 2.8 5.2 8.6 7.8 6.1 6.0 4.2 16.6 11.8 8.0 10.5 8.4 7.9 5.2 7.6 5.0 5.4 6.7 8.4 9.0 3.8 9.2 5.3 8.5 18.3 10.7 17.5 8.2 11.1 5.8 8.8 9.3 8.2 6.5 12.6 5.4 5.8 9.5 5.0 7.9 6.4 6.3 7.8 4.4 5.6 9.1 9.4 1.6 9.2 3.0 0.5 4.1 3.5 7.1 4.2 9.0 3.7 5.7 6.0 6.2 4.5 7.2 5.0 2.6 3.5 3.7 6.2 3.7 3.9 15.9 14.7 38.3 23.9 14.6 9.3 11.7 15.2 13.7 14.9 NR2C2 "hTAK1, TAK1, TR2R1, TR4" ENSG00000177463 "Nuclear receptor subfamily 2 group C member 2" P49116 3 14947584-15053600 "Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Differentiation, Spermatogenesis, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor, Repressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in all" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA006313 Approved Enhanced Nucleoplasm Nucleoplasm "HPA006313: AB_1079503" "unprognostic (1.32e-1)" "unprognostic (3.87e-1)" "unprognostic (3.98e-2)" "unprognostic (1.30e-1)" "unprognostic (1.04e-1)" "prognostic favourable (1.51e-5)" "unprognostic (1.03e-2)" "unprognostic (1.34e-1)" "unprognostic (1.05e-1)" "unprognostic (1.20e-1)" "unprognostic (1.29e-1)" "unprognostic (5.95e-2)" "unprognostic (1.02e-1)" "unprognostic (2.26e-1)" "unprognostic (1.25e-1)" "unprognostic (2.82e-2)" "unprognostic (5.82e-3)" 13.2 13.1 22.5 17.0 17.5 17.1 16.1 30.5 26.4 11.9 14.0 12.8 14.1 18.5 17.8 11.0 13.6 12.6 12.3 14.5 18.3 12.0 12.4 12.6 18.7 16.9 12.6 20.4 18.8 14.2 18.0 23.2 11.9 13.1 12.3 12.2 13.7 13.0 21.5 31.5 19.6 18.1 15.7 13.5 18.8 14.7 29.2 13.3 26.0 19.4 9.0 15.5 15.5 17.8 5.1 4.2 6.2 3.4 2.7 4.9 1.5 10.0 11.4 13.1 10.1 9.3 11.2 30.1 14.6 11.8 11.9 12.3 7.3 9.9 15.6 7.6 13.0 10.1 12.1 7.5 12.4 20.5 17.1 20.4 24.4 6.6 7.9 14.9 15.8 8.8 10.0 14.9 7.8 13.3 14.4 10.7 10.4 8.9 22.8 11.8 8.7 11.8 18.4 15.6 10.4 5.7 15.3 8.4 20.9 13.3 11.1 13.4 11.1 14.9 17.2 18.4 21.9 16.7 19.9 16.4 21.2 16.9 13.3 14.3 16.1 6.2 2.5 1.9 4.9 3.4 4.4 2.3 2.7 2.9 2.6 5.1 3.9 3.5 3.5 2.7 3.0 4.2 2.5 1.5 22.5 17.5 30.5 26.4 18.3 12.0 12.6 20.4 13.1 13.3 NR2E1 "TLL, TLX, XTLL" ENSG00000112333 "Nuclear receptor subfamily 2 group E member 1" Q9Y466 6 108166058-108188809 "Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Receptor, Repressor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enriched" "Detected in some" 6 "brain: 19.0" "Cell line enhanced" "Detected in some" "BEWO: 6.3;HEK 293: 2.2;RH-30: 1.6;U-251 MG: 8.1" "Cancer enriched" "Detected in single" 14 "glioma: 6.2" "Low region specificity" "Detected in many" "Cell type enriched" "Detected in single" 11 "neutrophil: 1.0" "Lineage enriched" "Detected in single" 11 "granulocytes: 1.0" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" "HPA036954, HPA055642" Uncertain Approved "Nuclear bodies" "Nuclear bodies" "HPA036954: AB_10670958, HPA055642: " "unprognostic (3.43e-1)" "unprognostic (1.41e-1)" "unprognostic (1.77e-1)" "unprognostic (9.60e-2)" "unprognostic (6.27e-2)" "unprognostic (6.00e-1)" "unprognostic (1.78e-2)" "unprognostic (7.31e-2)" "unprognostic (8.64e-2)" "unprognostic (9.59e-8)" "unprognostic (2.87e-1)" "unprognostic (2.49e-1)" "unprognostic (3.07e-1)" 0.6 1.1 14.5 0.6 16.0 0.8 0.8 0.0 19.0 0.6 0.6 2.8 0.0 0.7 0.6 0.6 0.6 0.6 0.6 0.7 10.8 4.3 0.9 0.6 0.6 0.7 3.5 7.5 0.7 0.7 0.8 0.1 0.7 0.0 0.6 0.6 3.3 1.0 0.6 0.7 0.9 0.6 0.6 0.0 0.7 0.7 0.8 4.1 0.0 0.7 0.0 0.6 0.7 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 6.3 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.0 2.2 1.0 0.1 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.2 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 1.6 0.0 0.0 0.4 0.0 0.1 0.0 0.0 0.0 0.1 0.1 0.1 0.0 0.0 0.0 8.1 0.0 0.0 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.0 0.0 0.0 0.0 0.0 0.0 14.5 16.0 0.0 10.0 10.8 4.3 3.5 7.5 0.0 4.1 NR2F1 "COUP-TFI, EAR-3, ERBAL3, SVP44, TCFCOUP1, TFCOUP1" ENSG00000175745 "Nuclear receptor subfamily 2 group F member 1" P10589 5 93583224-93594615 "Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor, Repressor" "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Cell line enhanced" "Detected in many" "AF22: 57.8;AN3-CA: 22.9;HHSteC: 44.5;PC-3: 47.8" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB019281, HPA058974" Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "CAB019281: , HPA058974: " "unprognostic (8.07e-2)" "unprognostic (1.06e-2)" "unprognostic (3.86e-2)" "unprognostic (2.26e-1)" "unprognostic (4.75e-1)" "unprognostic (7.68e-3)" "unprognostic (3.18e-3)" "unprognostic (3.07e-2)" "unprognostic (2.21e-1)" "unprognostic (2.71e-3)" "unprognostic (5.24e-3)" "unprognostic (2.37e-1)" "prognostic unfavourable (3.47e-4)" "unprognostic (1.32e-2)" "unprognostic (1.61e-1)" "unprognostic (9.28e-2)" "prognostic unfavourable (1.47e-4)" 15.8 22.9 22.5 5.0 13.7 1.2 9.1 27.4 25.1 31.7 4.6 12.9 10.8 3.3 20.6 24.1 9.4 32.3 30.7 7.2 20.9 13.7 16.4 10.6 18.0 12.7 13.4 23.0 40.4 4.4 1.8 10.3 46.0 14.6 20.5 3.8 44.4 7.2 38.9 1.2 1.6 4.4 14.2 26.7 6.7 12.9 5.9 11.4 0.0 7.5 4.8 4.2 20.9 18.0 0.0 0.0 0.5 0.1 0.2 0.0 0.0 4.7 2.3 57.8 22.9 12.3 3.8 2.7 2.8 1.1 1.7 1.8 0.3 0.8 0.0 0.1 1.1 1.2 1.4 0.0 0.7 5.8 11.1 2.2 14.0 3.5 44.5 0.4 0.2 17.7 0.0 0.8 0.3 6.4 0.0 0.0 5.2 0.0 0.0 0.6 0.0 47.8 0.6 0.4 0.0 0.3 0.2 5.9 12.1 1.2 0.0 0.1 0.4 0.9 6.4 9.8 0.4 5.1 7.0 0.0 0.0 0.0 16.1 0.2 4.2 0.3 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.2 0.1 0.0 0.0 0.0 22.5 13.7 27.4 19.8 20.9 13.7 13.4 23.0 14.6 11.4 NR2F2 "ARP1, COUP-TFII, COUPTFB, NF-E3, SVP40, TFCOUP2" ENSG00000185551 "Nuclear receptor subfamily 2 group F member 2" P24468 15 96325938-96340263 "Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Disease mutation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in many" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in single" 11 "memory CD8 T-cell: 1.1" "Lineage enriched" "Detected in single" 11 "T-cells: 1.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA058974 Approved Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA058974: " "unprognostic (9.28e-2)" "unprognostic (2.52e-2)" "unprognostic (2.34e-1)" "unprognostic (1.42e-2)" "unprognostic (8.96e-2)" "unprognostic (5.44e-2)" "unprognostic (3.38e-1)" "unprognostic (1.14e-1)" "unprognostic (2.61e-1)" "unprognostic (1.87e-1)" "unprognostic (1.89e-1)" "unprognostic (9.19e-2)" "unprognostic (5.14e-2)" "unprognostic (5.96e-2)" "unprognostic (1.72e-2)" "unprognostic (7.47e-2)" "unprognostic (1.28e-2)" 30.8 15.0 19.6 13.8 5.3 0.2 81.2 3.7 6.2 85.7 21.9 2.9 22.3 7.0 70.0 32.6 27.7 32.4 50.8 30.1 12.5 8.4 39.8 15.0 25.0 35.4 7.8 3.4 105.1 7.3 12.3 9.6 24.0 7.1 28.6 9.0 30.5 7.7 43.5 18.4 8.3 10.8 27.2 9.8 63.4 26.9 32.5 4.8 1.1 18.5 16.2 7.0 32.6 34.1 0.0 0.0 0.0 0.0 0.0 1.1 0.0 31.1 8.0 26.5 16.4 53.8 18.6 8.8 22.6 17.4 23.5 20.2 27.7 31.9 0.0 18.5 11.3 18.7 4.6 16.2 29.7 0.1 18.1 10.1 10.4 5.0 15.0 7.7 3.8 13.2 5.6 19.5 4.2 43.2 26.8 0.0 14.8 21.5 0.0 5.5 0.2 11.0 0.0 6.5 0.0 51.4 34.1 3.3 0.0 2.5 0.7 3.4 12.8 0.5 44.4 25.6 8.4 5.9 7.9 0.0 0.0 0.0 14.3 3.8 17.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 19.6 5.3 3.7 6.2 12.5 8.4 7.8 3.4 7.1 4.8 NR3C1 "GR, GRL" ENSG00000113580 "Nuclear receptor subfamily 3 group C member 1" P04150 5 143277931-143435512 "Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Apoptosis, Cell cycle, Cell division, Chromosome partition, Mitosis, Transcription, Transcription regulation" "Chromatin regulator, DNA-binding, Receptor, RNA-binding" "Disease mutation, FDA approved drug targets, Pseudohermaphroditism" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA004248, CAB010435" Supported Supported Nucleoplasm,Mitochondria,Cytosol "Nucleoplasm, Cytosol" Mitochondria "CAB010435: AB_2155784, HPA004248: AB_1078976" "unprognostic (1.38e-1)" "unprognostic (1.93e-1)" "unprognostic (1.17e-1)" "prognostic unfavourable (3.64e-5)" "unprognostic (1.43e-2)" "unprognostic (2.74e-1)" "unprognostic (4.19e-1)" "unprognostic (1.39e-1)" "unprognostic (2.46e-2)" "unprognostic (3.87e-2)" "unprognostic (2.15e-1)" "unprognostic (6.85e-2)" "prognostic unfavourable (1.72e-6)" "unprognostic (9.06e-3)" "unprognostic (1.02e-1)" "unprognostic (2.43e-3)" "unprognostic (2.45e-2)" 27.7 8.6 13.5 26.1 14.9 29.6 23.5 30.1 19.2 14.9 14.2 17.0 10.5 13.0 14.7 12.9 18.2 13.7 14.7 17.4 13.4 14.1 13.5 27.3 22.0 16.1 18.3 12.8 15.5 12.5 21.9 18.9 31.9 13.6 14.3 10.3 14.2 12.0 15.2 40.4 18.3 14.8 16.8 17.2 17.5 13.4 7.3 18.2 37.1 18.0 15.1 18.2 14.8 32.2 11.1 13.6 33.7 11.8 10.9 9.6 7.3 10.0 20.5 1.5 0.0 13.5 15.1 1.8 15.8 18.9 13.6 15.8 1.5 13.5 8.9 7.2 23.1 9.6 0.1 12.4 16.9 5.0 7.0 2.3 27.8 4.4 12.7 9.2 7.1 10.9 16.1 22.4 21.9 5.1 3.3 34.0 12.0 3.6 5.4 6.6 4.1 4.3 1.9 14.3 18.9 4.0 0.7 2.7 2.1 27.6 4.0 6.6 1.8 13.3 12.1 33.2 6.6 15.8 11.9 6.9 6.2 14.0 17.4 9.5 11.5 25.4 9.8 17.9 9.3 11.8 7.7 7.6 9.6 8.9 13.6 11.1 9.2 8.9 33.7 10.9 10.5 12.4 5.8 7.3 13.5 14.9 30.1 19.2 13.4 14.1 18.3 12.8 13.6 18.2 NR3C2 "MLR, MR" ENSG00000151623 "Nuclear receptor subfamily 3 group C member 2" P08235 4 148078762-148444698 "Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "HUVEC TERT2: 7.1;Karpas-707: 7.7;PC-3: 7.1;RPTEC TERT1: 9.6;TIME: 9.4;U-138 MG: 5.1" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 4.8" "Lineage enriched" "Detected in single" 6 "T-cells: 4.8" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB009155, HPA074979" Enhanced Supported Nucleoplasm Nucleoplasm "CAB009155: AB_2155949, HPA074979: " "unprognostic (2.75e-3)" "unprognostic (2.63e-2)" "unprognostic (6.70e-3)" "unprognostic (1.52e-1)" "unprognostic (4.09e-1)" "unprognostic (7.82e-3)" "unprognostic (1.04e-2)" "unprognostic (1.11e-2)" "unprognostic (1.14e-1)" "unprognostic (4.35e-2)" "unprognostic (4.97e-2)" "unprognostic (2.39e-1)" "prognostic favourable (3.10e-11)" "unprognostic (1.42e-1)" "unprognostic (1.87e-1)" "unprognostic (1.57e-1)" "unprognostic (1.27e-1)" 7.0 5.6 9.0 12.9 9.5 1.5 7.2 16.8 14.5 8.2 23.4 8.2 6.5 9.7 7.2 4.8 3.8 7.1 10.2 9.7 12.7 6.5 13.8 9.6 8.2 4.2 7.5 7.7 17.0 8.6 22.5 16.7 2.4 5.7 5.9 28.4 12.1 16.9 9.6 12.1 4.6 26.5 8.6 6.5 5.7 9.0 4.8 6.5 2.2 21.7 7.6 5.0 10.7 5.6 0.8 0.0 0.0 0.4 0.1 4.8 0.4 0.0 0.0 0.0 0.0 0.5 0.4 0.5 0.0 0.1 0.0 0.5 0.0 0.1 1.6 3.0 1.2 0.0 1.6 0.8 0.1 0.3 2.9 0.3 0.7 0.0 0.1 1.9 0.4 0.1 0.0 0.1 0.0 7.1 0.0 7.7 2.4 0.0 0.0 0.0 0.1 7.1 0.6 0.0 0.1 9.6 0.1 0.1 0.1 0.0 1.6 0.7 0.9 0.0 9.4 5.1 3.0 0.2 0.9 0.0 0.0 0.2 1.7 0.7 1.2 0.0 0.0 0.0 1.5 0.0 4.8 0.4 1.8 1.2 0.0 0.8 2.9 2.9 0.0 0.1 0.4 0.0 0.5 0.4 9.0 9.5 16.8 14.5 12.7 6.5 7.5 7.7 5.7 6.5 NR4A1 "GFRP1, HMR, N10, NAK-1, NGFIB, NUR77, TR3" ENSG00000123358 "Nuclear receptor subfamily 4 group A member 1" P22736 12 52022832-52059507 "Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HeLa: 25.3;MCF7: 28.8;SK-BR-3: 27.3;SK-MEL-30: 47.6" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in some" 12 "intermediate monocyte: 18.2;non-classical monocyte: 24.4" "Lineage enriched" "Detected in many" 13 "monocytes: 24.4" "Group enriched" "Detected in many" 5 "amygdala: 35.3;basal ganglia: 43.1;cerebral cortex: 77.4;hippocampal formation: 65.3;olfactory region: 79.3" "Low region specificity" "Detected in all" "HPA059742, HPA070142" Approved Supported "Nucleoplasm,Nuclear membrane,Cytosol" Nucleoplasm "Nuclear membrane, Cytosol" "HPA059742: AB_2684119, HPA070142: " "unprognostic (2.40e-2)" "unprognostic (2.57e-1)" "unprognostic (1.29e-1)" "unprognostic (1.74e-1)" "unprognostic (1.65e-1)" "unprognostic (1.16e-1)" "unprognostic (1.26e-2)" "unprognostic (1.94e-1)" "unprognostic (1.92e-2)" "unprognostic (2.22e-3)" "unprognostic (1.90e-1)" "unprognostic (1.16e-1)" "prognostic favourable (6.99e-4)" "unprognostic (3.41e-2)" "unprognostic (2.71e-1)" "unprognostic (1.84e-2)" "unprognostic (8.89e-3)" 69.1 111.3 4.0 58.1 12.9 5.7 25.0 5.4 10.9 32.3 23.3 21.1 46.0 5.6 49.8 33.9 28.1 63.3 99.9 76.7 4.8 5.0 17.9 12.1 50.1 8.3 7.5 5.9 177.3 16.1 28.9 51.8 7.6 13.1 88.3 13.8 43.7 66.8 203.2 32.3 23.4 24.3 98.4 6.8 5.1 32.8 11.8 6.4 11.9 34.7 35.8 14.9 71.4 54.5 0.4 1.8 0.2 24.4 0.1 0.2 0.7 1.8 9.5 1.8 3.4 1.3 0.4 7.2 1.8 3.6 1.4 2.0 9.3 1.8 2.0 0.8 3.2 1.0 5.6 0.8 0.8 0.1 2.0 2.6 25.3 2.6 1.4 1.0 8.9 0.3 1.1 1.4 0.1 0.4 2.5 0.4 0.1 28.8 0.7 2.7 5.2 1.0 0.8 0.3 4.7 0.0 0.7 1.5 4.7 5.9 27.3 47.6 1.7 3.0 0.0 1.4 4.6 0.9 1.5 16.1 7.6 4.1 0.9 0.7 7.9 0.1 0.6 0.0 0.1 18.2 0.1 0.4 0.0 0.0 1.8 0.4 0.2 0.0 0.2 0.1 24.4 0.1 0.1 0.7 4.0 12.9 5.4 10.9 4.8 5.0 7.5 5.9 13.1 6.4 NR4A2 "HZF-3, NOT, NURR1, RNR1, TINUR" ENSG00000153234 "Nuclear receptor subfamily 4 group A member 2" P43354 2 156324432-156342348 "Cancer-related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "seminal vesicle: 102.1" "Cell line enhanced" "Detected in many" "HeLa: 14.2;HMC-1: 10.5;U-266/70: 14.2" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 10.1" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA000543, CAB010481" Uncertain Supported "Nuclear speckles" "Nuclear speckles" "CAB010481: AB_2298676, HPA000543: AB_1854631" "unprognostic (4.26e-2)" "unprognostic (2.14e-1)" "unprognostic (3.42e-2)" "unprognostic (4.10e-2)" "unprognostic (3.04e-2)" "unprognostic (5.26e-2)" "unprognostic (2.30e-1)" "unprognostic (6.14e-2)" "unprognostic (8.63e-2)" "unprognostic (3.88e-2)" "unprognostic (1.60e-2)" "unprognostic (2.89e-1)" "unprognostic (2.39e-2)" "unprognostic (3.58e-2)" "unprognostic (3.43e-1)" "unprognostic (9.29e-3)" "unprognostic (1.11e-1)" 15.0 58.5 3.1 10.2 5.7 49.1 7.5 15.2 14.4 9.1 4.2 7.3 11.0 1.4 6.4 7.5 5.7 13.6 21.3 15.8 5.2 2.6 5.9 7.6 12.5 2.8 4.8 4.2 60.0 4.2 8.7 23.7 2.3 5.1 11.7 8.5 5.3 18.0 102.1 6.1 5.3 6.0 8.4 5.9 2.1 8.3 3.8 3.7 2.1 6.8 8.0 5.3 17.8 7.5 0.7 2.8 10.1 2.3 0.0 1.6 0.6 0.8 1.2 0.5 1.7 3.1 0.6 0.8 1.0 5.2 0.4 1.3 0.0 3.6 0.0 1.2 0.4 1.5 2.5 0.7 0.4 1.2 1.3 0.9 14.2 0.0 0.6 0.8 10.5 0.6 1.1 0.4 0.4 0.3 1.4 1.0 1.0 1.7 0.0 0.8 2.2 0.9 0.2 0.7 3.0 0.6 0.8 2.6 0.1 2.5 3.9 6.9 0.2 0.9 0.7 2.8 0.8 0.7 0.4 14.2 1.5 0.0 5.2 0.9 6.6 3.0 2.3 3.4 1.6 0.5 0.9 0.7 0.5 0.8 2.8 0.5 0.9 0.4 10.1 0.0 0.9 0.0 0.5 0.6 3.1 5.7 15.2 14.4 5.2 2.6 4.8 4.2 5.1 3.7 NR4A3 "CHN, CSMF, MINOR, NOR1" ENSG00000119508 "Nuclear receptor subfamily 4 group A member 3" Q92570 9 99821855-99866891 "Cancer-related genes, Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Proto-oncogene" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "seminal vesicle: 80.6" "Group enriched" "Detected in some" 5 "BJ hTERT+: 21.0;HeLa: 7.3;SK-MEL-30: 14.5;U-266/70: 8.6" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "eosinophil: 1.3;NK-cell: 1.3" "Group enriched" "Detected in many" 6 "granulocytes: 1.3;NK-cells: 1.3" "Low region specificity" "Detected in many" "Low region specificity" "Detected in many" HPA043360 Uncertain "HPA043360: AB_10961186" "prognostic favourable (5.97e-4)" "unprognostic (6.92e-3)" "unprognostic (5.34e-2)" "unprognostic (2.78e-3)" "unprognostic (1.40e-1)" "unprognostic (9.46e-2)" "unprognostic (2.89e-2)" "unprognostic (3.30e-2)" "unprognostic (2.65e-3)" "unprognostic (1.40e-2)" "unprognostic (2.28e-1)" "unprognostic (3.30e-1)" "unprognostic (2.25e-1)" "unprognostic (1.29e-3)" "unprognostic (6.11e-2)" "unprognostic (2.80e-2)" "unprognostic (1.69e-1)" 19.9 46.5 3.5 10.2 4.5 22.1 5.9 1.6 5.0 9.7 4.8 9.5 6.3 0.8 10.7 6.1 3.1 15.7 16.6 37.3 4.1 2.5 3.8 7.1 12.4 1.2 1.6 3.1 37.2 4.0 4.0 12.2 4.7 5.0 12.0 3.2 7.0 1.6 80.6 28.5 1.5 4.2 23.0 5.1 2.6 9.0 1.3 3.4 7.6 4.2 15.5 1.9 23.5 7.5 0.0 0.2 1.3 0.0 1.3 0.0 0.0 0.1 0.1 0.6 0.1 1.2 0.4 1.0 1.3 21.0 0.2 0.2 0.2 0.1 0.1 0.3 0.5 0.1 0.4 0.0 0.1 1.8 0.3 0.1 7.3 0.0 0.1 0.1 2.0 0.3 0.0 0.5 0.1 0.0 0.0 0.5 0.1 0.6 0.0 0.2 0.0 0.6 0.0 0.9 0.0 0.0 0.1 0.4 0.4 2.3 1.7 14.5 0.0 0.0 0.1 1.4 0.4 1.7 0.1 8.6 0.1 0.0 0.9 0.0 0.8 0.0 0.0 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.8 1.3 0.0 0.0 0.0 0.0 3.5 4.5 1.6 5.0 4.1 2.5 1.6 3.1 5.0 3.4 NR5A2 "B1F2, FTF, FTZ-F1, FTZ-F1beta, hB1F, hB1F-2, LRH-1" ENSG00000116833 "Nuclear receptor subfamily 5 group A member 2" O00482 1 200027602-200177424 "Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 10 "intestine: 38.7;liver: 36.1;pancreas: 100.4" "Cell line enhanced" "Detected in some" "A549: 19.3;HAP1: 11.7;HMC-1: 5.1;HUVEC TERT2: 16.1" "Cancer enhanced" "Detected in many" "liver cancer: 6.6" "Not detected" "Not detected" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Region enhanced" "Detected in single" "hypothalamus: 1.5" "HPA005455, HPA017067" Approved Uncertain "Nuclear speckles" "Nuclear speckles" "HPA005455: AB_1078140, HPA017067: AB_1844767" "unprognostic (7.47e-2)" "unprognostic (1.43e-1)" "unprognostic (5.84e-2)" "unprognostic (1.56e-2)" "unprognostic (1.19e-2)" "unprognostic (6.63e-3)" "unprognostic (4.46e-2)" "unprognostic (3.78e-2)" "unprognostic (3.34e-1)" "unprognostic (8.50e-2)" "unprognostic (4.64e-2)" "unprognostic (1.44e-1)" "unprognostic (1.00e-7)" "unprognostic (5.48e-2)" "unprognostic (5.07e-2)" "unprognostic (9.23e-2)" "unprognostic (1.37e-1)" 2.9 0.2 0.2 4.5 0.3 0.0 2.6 0.2 0.2 2.3 23.8 0.2 0.6 8.1 3.5 1.3 0.7 1.3 5.7 0.5 0.2 0.4 0.4 36.1 1.6 0.7 0.3 0.3 1.0 100.4 0.0 0.3 0.3 0.3 1.1 6.3 0.3 0.5 1.3 1.0 0.7 38.7 1.8 0.4 0.3 0.6 0.6 0.2 0.2 0.8 0.3 0.4 0.8 1.1 1.3 1.4 5.5 1.2 1.5 1.1 0.3 0.0 19.3 0.0 0.1 0.0 0.2 0.5 0.0 0.3 0.0 0.0 4.3 0.1 0.0 0.0 0.0 0.5 11.7 0.0 0.0 2.5 0.8 0.0 0.2 2.0 0.4 0.0 5.1 0.1 0.0 0.0 0.1 16.1 0.0 0.3 0.0 0.5 0.0 0.3 0.8 0.3 0.3 0.0 0.1 0.0 0.1 0.0 0.0 0.0 0.1 0.1 3.7 0.3 0.1 0.8 0.2 0.1 0.1 2.7 1.7 2.0 0.3 0.1 0.1 5.5 1.2 1.1 0.6 0.7 0.7 0.7 1.0 0.8 0.4 1.3 1.1 1.0 4.2 1.5 0.5 1.4 0.9 0.3 0.2 0.3 0.2 0.2 0.2 0.4 0.3 0.3 0.3 0.2 NR6A1 "CT150, GCNF, GCNF1, RTR" ENSG00000148200 "Nuclear receptor subfamily 6 group A member 1" Q15406 9 124517275-124771310 "Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "testis: 28.2" "Cell line enhanced" "Detected in some" "BEWO: 47.0;CACO-2: 10.8;Hep G2: 10.5;K-562: 13.8;NTERA-2: 16.7;U-266/84: 10.1" "Cancer enriched" "Detected in many" 16 "testis cancer: 27.8" "Low region specificity" "Detected in all" "Cell type enriched" "Detected in some" 4 "neutrophil: 8.6" "Lineage enriched" "Detected in many" 7 "granulocytes: 8.6" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" "HPA031461, HPA045145" Supported Nucleoplasm,Centrosome,Cytosol Nucleoplasm "Centrosome, Cytosol" "HPA031461: , HPA045145: " "unprognostic (1.73e-1)" "unprognostic (6.66e-2)" "unprognostic (4.53e-1)" "unprognostic (1.34e-6)" "unprognostic (4.40e-2)" "unprognostic (3.20e-2)" "unprognostic (2.52e-5)" "unprognostic (6.31e-2)" "unprognostic (8.01e-3)" "unprognostic (2.71e-2)" "unprognostic (1.58e-2)" "unprognostic (1.63e-1)" "unprognostic (7.26e-2)" "unprognostic (7.20e-3)" "unprognostic (1.71e-1)" "unprognostic (6.77e-3)" "unprognostic (1.09e-1)" 0.6 1.0 2.9 1.4 3.4 5.5 1.8 5.8 3.5 0.8 7.9 1.2 1.3 2.5 0.9 1.4 2.2 1.0 0.9 1.0 3.3 1.3 1.9 2.8 1.8 0.7 2.1 2.4 0.6 3.3 1.5 2.2 4.2 2.2 1.7 2.3 1.7 1.5 1.4 1.9 2.6 5.3 0.8 2.3 1.1 0.7 28.2 2.8 0.0 7.3 0.8 1.1 1.3 1.4 0.3 1.0 8.6 1.2 0.1 0.0 0.1 0.5 1.2 6.2 0.8 0.1 0.1 47.0 0.0 0.4 0.3 0.5 10.8 1.2 2.1 0.4 0.0 1.1 0.6 0.5 0.7 0.5 2.0 1.6 1.7 10.5 0.0 0.9 3.1 0.0 0.6 0.5 0.6 0.1 13.8 0.3 0.2 0.2 0.0 1.3 16.7 0.5 0.5 0.6 0.9 0.2 0.8 0.9 0.3 0.0 0.3 0.4 1.1 0.5 0.0 0.6 1.3 0.4 0.3 1.4 10.1 1.9 0.3 0.9 0.3 0.1 1.2 2.0 0.0 0.9 0.0 0.1 0.0 0.0 1.0 0.3 0.0 0.0 8.6 0.1 0.6 0.2 0.0 0.1 2.9 3.4 5.8 3.5 3.3 1.3 2.1 2.4 2.2 2.8 PGR "NR3C3, PR" ENSG00000082175 "Progesterone receptor" P06401 11 101029624-101130524 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 5 "cervix, uterine: 50.7;endometrium 1: 116.4;smooth muscle: 31.2" "Cell line enriched" "Detected in single" 349 "T-47d: 60.8" "Group enriched" "Detected in some" 13 "breast cancer: 10.1;endometrial cancer: 11.1" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Not detected" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" "CAB000068, HPA004751, HPA008428, HPA017176, CAB055100" Enhanced "CAB000068: AB_442124, CAB055100: AB_2532076, HPA004751: AB_1079681, HPA008428: AB_1079680, HPA017176: AB_1855728" "unprognostic (2.59e-2)" "unprognostic (9.80e-3)" "unprognostic (5.23e-3)" "prognostic favourable (5.76e-8)" "unprognostic (2.81e-2)" "unprognostic (1.56e-1)" "unprognostic (4.11e-1)" "unprognostic (1.64e-1)" "unprognostic (2.08e-1)" "unprognostic (2.50e-1)" "unprognostic (3.29e-2)" "unprognostic (1.77e-1)" "unprognostic (7.71e-3)" "unprognostic (1.90e-2)" "unprognostic (2.35e-2)" "unprognostic (1.15e-1)" "unprognostic (5.44e-3)" 0.8 0.7 0.2 0.3 0.6 0.0 5.0 0.2 0.7 50.7 1.3 0.2 0.4 0.0 116.4 6.1 0.5 13.2 0.4 2.0 0.5 0.6 0.4 0.1 1.2 0.3 0.4 0.1 10.6 0.8 0.0 2.8 1.8 0.8 3.8 0.1 0.7 3.5 5.5 0.3 0.3 1.2 31.2 0.9 0.5 0.4 1.5 0.3 0.1 0.3 0.8 0.2 1.1 6.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 60.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.6 0.2 0.7 0.5 0.6 0.4 0.1 0.8 0.3 PPARA "hPPAR, NR1C1, PPAR" ENSG00000186951 "Peroxisome proliferator activated receptor alpha" Q07869 22 46150521-46243756 "FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Group enriched" "Detected in many" 4 "eosinophil: 12.1;plasmacytoid DC: 3.8" "Group enriched" "Detected in many" 5 "dendritic cells: 3.8;granulocytes: 12.1" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA058901, HPA067049, CAB075701" Supported Enhanced Nucleoplasm Nucleoplasm "CAB075701: , HPA058901: , HPA067049: " "unprognostic (1.96e-1)" "unprognostic (2.19e-1)" "unprognostic (1.02e-1)" "unprognostic (4.76e-2)" "unprognostic (3.94e-3)" "unprognostic (4.30e-2)" "unprognostic (1.24e-1)" "unprognostic (4.94e-2)" "unprognostic (2.95e-1)" "unprognostic (5.52e-3)" "unprognostic (4.50e-2)" "unprognostic (1.01e-1)" "prognostic favourable (4.39e-9)" "unprognostic (4.84e-2)" "unprognostic (2.76e-1)" "unprognostic (1.23e-1)" "unprognostic (3.18e-2)" 5.7 6.6 5.8 6.0 6.2 4.2 6.9 2.6 4.5 3.8 11.8 5.9 9.9 13.9 4.8 6.6 6.3 3.9 9.1 19.6 5.1 4.1 17.8 30.9 3.8 3.4 6.1 4.9 9.1 13.4 6.6 3.5 3.1 7.8 6.2 7.1 13.5 8.1 8.2 17.1 5.8 19.7 5.0 4.7 3.5 5.7 2.7 7.1 1.3 5.4 10.4 4.8 7.3 12.3 1.5 3.8 12.1 1.4 0.9 1.5 0.3 6.8 1.7 2.1 7.6 12.1 7.8 4.8 5.9 11.9 6.4 6.6 3.3 3.3 2.4 3.0 13.8 3.1 6.4 7.8 5.8 7.0 8.1 7.6 4.3 7.0 7.6 5.1 13.0 6.1 6.3 4.7 10.9 1.3 2.7 5.7 5.9 1.7 5.8 1.9 0.3 1.7 6.9 7.8 3.2 4.4 4.0 2.1 6.4 2.3 2.1 7.5 2.4 4.0 2.3 6.7 7.2 6.0 2.6 5.7 3.3 1.0 10.5 5.8 2.0 1.7 1.0 12.1 1.4 1.4 1.2 1.0 0.7 0.7 0.7 1.5 0.8 0.6 0.8 0.9 0.8 3.8 1.5 0.3 5.8 6.2 2.6 4.5 5.1 4.1 6.1 4.9 7.8 7.1 PPARD "FAAR, NR1C2, NUC1, NUCII" ENSG00000112033 "Peroxisome proliferator activated receptor delta" Q03181 6 35342558-35428191 "FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Low cell line specificity" "Detected in many" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in all" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB017635 Approved "CAB017635: AB_1128605" "unprognostic (3.70e-2)" "unprognostic (8.75e-2)" "unprognostic (1.00e-1)" "unprognostic (1.89e-1)" "unprognostic (1.57e-1)" "unprognostic (8.68e-2)" "prognostic unfavourable (4.57e-4)" "unprognostic (4.59e-3)" "unprognostic (4.34e-1)" "unprognostic (1.45e-1)" "unprognostic (1.05e-1)" "unprognostic (1.51e-3)" "unprognostic (7.27e-3)" "unprognostic (1.43e-1)" "unprognostic (9.42e-2)" "unprognostic (5.95e-2)" "unprognostic (2.00e-2)" 16.4 13.4 20.4 19.4 21.8 8.8 11.3 19.0 29.5 14.0 19.0 20.4 24.5 12.7 15.0 22.7 29.6 13.4 16.7 15.7 23.8 14.5 11.9 19.9 18.1 15.6 22.5 14.6 21.6 11.1 14.2 16.2 30.4 19.8 18.0 13.9 15.4 15.2 20.6 22.5 26.3 16.5 12.8 20.9 20.0 23.4 12.8 20.8 6.2 26.8 9.5 15.8 14.5 19.4 4.4 2.9 6.7 3.5 2.3 5.6 2.5 20.7 3.7 5.9 12.5 8.7 15.4 31.9 17.0 15.3 14.7 12.3 5.0 3.9 3.4 5.0 12.1 7.5 5.5 16.5 10.3 4.8 5.0 3.1 4.9 7.3 15.3 0.7 3.6 26.1 5.5 21.7 11.2 6.8 3.3 3.8 12.3 6.5 2.2 3.3 2.8 10.1 3.2 10.1 3.3 3.6 18.6 3.3 9.2 6.8 11.9 14.5 4.4 11.6 14.7 20.1 7.6 12.0 20.2 3.2 4.4 3.7 6.5 6.7 8.9 1.1 3.5 6.7 3.1 3.3 2.2 3.4 3.3 3.0 2.9 4.4 5.6 5.1 5.4 2.3 1.9 1.8 3.2 2.5 20.4 21.8 19.0 29.5 23.8 14.5 22.5 14.6 19.8 20.8 PPARG "NR1C3, PPARG1, PPARG2, PPARgamma" ENSG00000132170 "Peroxisome proliferator activated receptor gamma" P37231 3 12287368-12434356 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, DNA-binding, Receptor" "Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets, Obesity" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "adipose tissue: 97.6;breast: 102.1" "Cell line enhanced" "Detected in many" "ASC diff: 47.4;ASC TERT1: 27.0;BEWO: 55.9;CAPAN-2: 25.0;HSkMC: 27.8;PC-3: 24.9;RT4: 34.1" "Cancer enhanced" "Detected in all" "urothelial cancer: 33.5" "Low region specificity" "Detected in many" "Cell type enhanced" "Detected in some" "classical monocyte: 1.8;intermediate monocyte: 2.3" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Not detected" "Not detected" "CAB004282, HPA051239, HPA063663" Approved Enhanced Nucleoplasm,Vesicles "Nucleoplasm, Vesicles" "CAB004282: AB_628115, HPA051239: , HPA063663: " "unprognostic (7.35e-3)" "unprognostic (3.27e-2)" "unprognostic (4.05e-2)" "unprognostic (8.37e-2)" "unprognostic (2.41e-2)" "unprognostic (5.27e-3)" "prognostic unfavourable (3.41e-5)" "unprognostic (9.13e-2)" "unprognostic (2.32e-2)" "unprognostic (1.38e-1)" "unprognostic (1.02e-2)" "unprognostic (2.77e-1)" "prognostic favourable (1.59e-8)" "unprognostic (1.51e-2)" "unprognostic (1.46e-1)" "unprognostic (9.68e-3)" "prognostic favourable (5.52e-5)" 97.6 1.6 1.9 17.1 1.2 0.7 102.1 1.5 1.3 3.1 24.9 0.8 2.1 7.5 3.5 2.2 2.8 2.4 8.7 12.5 1.4 0.9 6.7 5.9 24.8 11.4 1.1 0.9 6.7 1.2 2.8 0.3 26.8 0.9 10.4 13.9 1.1 5.8 1.5 5.0 2.7 9.6 7.4 1.2 7.0 11.9 3.5 0.6 0.9 6.2 4.3 2.1 30.2 14.1 0.0 0.4 0.0 2.3 0.0 0.7 0.3 9.6 8.6 0.0 0.0 47.4 27.0 55.9 0.9 10.4 1.3 0.5 1.8 25.0 0.0 0.0 0.9 3.9 3.4 0.1 0.2 23.2 4.8 0.0 1.9 2.3 12.6 0.0 0.0 27.8 2.3 2.3 9.0 0.1 0.0 0.0 2.0 2.4 0.0 0.1 0.1 24.9 0.0 0.0 0.0 7.1 34.1 0.0 0.2 4.0 1.5 0.5 0.0 7.7 7.8 1.8 2.6 1.0 0.0 0.0 0.0 0.0 0.8 0.1 0.2 0.0 1.8 0.0 0.0 2.3 0.0 0.0 0.7 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.3 1.9 1.2 1.5 1.3 1.4 0.9 1.1 0.9 0.9 0.6 RARA "NR1B1, RAR" ENSG00000131759 "Retinoic acid receptor alpha" P10276 17 40309192-40357643 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in all" "MCF7: 63.1;SK-BR-3: 40.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 26.6" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" HPA058282 Supported Nucleoplasm,Cytosol Nucleoplasm Cytosol "HPA058282: " "unprognostic (8.05e-3)" "unprognostic (1.89e-1)" "unprognostic (9.48e-3)" "prognostic favourable (2.60e-4)" "unprognostic (8.67e-3)" "unprognostic (4.87e-3)" "unprognostic (2.77e-1)" "unprognostic (5.73e-2)" "unprognostic (1.45e-1)" "unprognostic (3.54e-2)" "unprognostic (1.19e-1)" "unprognostic (1.79e-1)" "unprognostic (2.29e-3)" "unprognostic (1.59e-2)" "unprognostic (5.60e-2)" "unprognostic (1.60e-1)" "unprognostic (1.09e-2)" 27.6 13.5 5.0 18.6 7.6 32.3 23.7 11.5 15.2 30.2 29.6 5.0 16.8 18.0 23.8 23.9 17.3 23.3 30.2 24.3 5.9 6.1 14.6 24.0 32.0 23.4 4.6 7.8 50.0 9.3 7.4 18.1 16.6 6.5 22.9 8.5 26.8 12.1 32.7 43.1 14.3 31.6 18.6 3.7 31.1 14.3 21.8 2.9 9.7 16.3 15.4 20.2 31.5 20.3 1.0 6.1 26.6 9.3 2.5 2.6 1.9 5.0 11.9 3.6 6.0 7.0 10.8 3.6 4.2 6.3 6.2 4.0 8.2 4.4 2.7 6.6 9.4 14.9 4.1 9.9 3.5 20.2 6.1 7.7 6.0 8.0 11.3 2.7 24.4 15.1 2.9 6.5 8.3 9.1 4.8 5.9 6.9 63.1 1.7 9.4 3.1 3.8 3.6 21.1 10.2 3.6 4.0 1.5 12.2 8.9 40.1 12.2 37.8 11.1 10.6 7.7 13.2 13.5 4.5 14.2 4.7 2.3 12.9 5.5 22.8 8.7 4.2 15.7 1.6 6.9 2.6 1.0 1.7 1.7 6.1 0.9 0.8 1.3 26.6 2.5 9.3 1.8 1.4 1.9 5.0 7.6 11.5 15.2 5.9 6.1 4.6 7.8 6.5 2.9 RARB "HAP, NR1B2, RRB2" ENSG00000077092 "Retinoic acid receptor beta" P10826 3 25174332-25597932 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Disease mutation, FDA approved drug targets, Microphthalmia, Proto-oncogene" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "retina: 39.1" "Cell line enhanced" "Detected in some" "ASC diff: 9.9;HEK 293: 11.2;HUVEC TERT2: 9.3;WM-115: 25.6" "Low cancer specificity" "Detected in all" "Region enhanced" "Detected in all" "basal ganglia: 22.6" "Low cell type specificity" "Detected in single" "Low lineage specificity" "Detected in single" "Region enriched" "Detected in many" 9 "basal ganglia: 97.9" "Low region specificity" "Detected in all" "CAB002617, HPA004174" Enhanced Enhanced Nucleoplasm Nucleoplasm "CAB002617: , HPA004174: AB_1079744" "unprognostic (2.04e-2)" "unprognostic (3.53e-2)" "unprognostic (1.93e-1)" "unprognostic (1.09e-1)" "unprognostic (1.56e-1)" "unprognostic (6.72e-2)" "unprognostic (1.30e-2)" "unprognostic (2.70e-2)" "unprognostic (2.43e-1)" "unprognostic (4.71e-2)" "unprognostic (1.62e-1)" "unprognostic (2.86e-1)" "prognostic favourable (3.43e-5)" "unprognostic (9.24e-3)" "unprognostic (2.28e-1)" "unprognostic (9.99e-2)" "unprognostic (6.56e-3)" 3.9 7.1 2.4 2.3 22.6 0.0 6.8 1.5 9.1 13.4 6.0 2.2 6.8 1.7 14.4 7.5 8.1 6.2 5.3 13.6 2.6 2.2 17.5 6.2 5.6 5.6 2.0 3.7 12.2 1.5 12.8 18.9 13.9 3.2 13.0 2.3 39.1 13.7 11.8 2.5 1.4 2.4 14.7 4.6 7.7 4.8 1.7 4.8 0.0 10.0 2.9 4.6 12.1 10.2 1.0 0.4 0.1 0.6 0.1 0.8 0.0 0.0 1.3 0.8 4.5 9.9 2.6 0.0 1.1 0.5 0.0 0.4 0.2 0.0 0.1 0.1 1.7 0.2 0.0 0.1 0.0 0.0 11.2 0.1 0.1 0.7 0.2 0.1 0.1 5.2 0.0 0.0 0.0 9.3 0.1 3.9 0.1 0.0 0.0 0.1 0.2 0.0 0.2 0.0 0.0 0.0 0.1 0.4 5.9 0.0 0.1 0.1 0.0 0.0 0.0 0.8 0.1 1.5 4.8 0.1 0.0 0.0 4.0 0.1 25.6 0.0 0.6 0.0 0.8 0.1 0.3 0.3 0.5 0.5 0.4 1.0 0.6 0.8 0.1 0.1 0.1 0.4 0.0 0.0 2.4 22.6 1.5 9.1 2.6 2.2 2.0 3.7 3.2 4.8 RARG "NR1B3, RARC" ENSG00000172819 "Retinoic acid receptor gamma" P13631 12 53210567-53232980 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "esophagus: 49.4;skin 1: 52.1" "Cell line enhanced" "Detected in many" "CAPAN-2: 33.2;MCF7: 35.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "MAIT T-cell: 17.0" "Group enriched" "Detected in all" 4 "dendritic cells: 5.6;T-cells: 17.0" "Low region specificity" "Detected in all" "Low region specificity" "Detected in many" HPA053883 Supported Supported Nucleoplasm Nucleoplasm "HPA053883: AB_2682292" "unprognostic (7.29e-2)" "unprognostic (1.95e-2)" "unprognostic (6.11e-2)" "prognostic unfavourable (3.68e-6)" "unprognostic (2.53e-1)" "unprognostic (5.43e-2)" "unprognostic (2.28e-1)" "unprognostic (1.08e-2)" "unprognostic (3.54e-3)" "unprognostic (7.21e-3)" "unprognostic (3.78e-3)" "unprognostic (4.44e-2)" "prognostic unfavourable (3.08e-6)" "unprognostic (5.41e-3)" "unprognostic (1.98e-2)" "unprognostic (5.94e-3)" "unprognostic (7.41e-2)" 4.8 5.0 2.7 7.0 3.6 1.3 10.8 6.3 3.8 26.8 6.3 1.8 7.3 1.0 14.6 6.0 49.4 10.6 8.6 6.9 3.0 1.4 3.7 1.9 7.4 6.7 2.4 2.3 12.6 2.7 4.2 2.8 4.4 1.6 11.3 3.4 10.3 9.5 10.6 2.6 52.1 3.0 9.7 1.5 4.7 6.0 3.9 1.7 2.3 7.3 30.6 26.8 10.9 19.8 1.8 5.6 1.5 2.5 1.7 17.0 2.9 7.2 8.0 1.8 16.9 18.8 16.2 0.5 7.6 16.6 10.0 7.8 2.7 33.2 0.1 4.1 30.5 24.4 6.1 14.6 2.5 1.9 3.1 1.0 6.1 2.3 7.9 0.0 3.0 11.9 21.4 9.5 2.1 4.2 0.2 3.2 3.9 35.0 0.4 0.3 5.4 14.1 2.3 0.6 5.8 2.9 12.0 1.5 7.6 15.4 16.7 10.1 14.5 0.4 4.5 12.0 5.6 7.9 0.4 1.5 0.8 0.5 14.7 1.2 16.9 1.5 2.5 0.7 6.6 0.8 17.0 1.8 5.7 4.8 5.6 0.6 4.8 4.1 0.0 1.7 0.0 0.4 1.5 2.9 2.7 3.6 6.3 3.8 3.0 1.4 2.4 2.3 1.6 1.7 RORA "NR1F1, ROR1, ROR2, ROR3, RZRA" ENSG00000069667 "RAR related orphan receptor A" P35398 15 60488284-61229319 "Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Receptor" "Disease mutation, Epilepsy, Mental retardation" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "skin 1: 64.8" "Cell line enhanced" "Detected in many" "Karpas-707: 34.3;U-266/70: 19.7;U-266/84: 27.2" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Lineage enriched" "Detected in many" 4 "T-cells: 16.9" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" CAB009861 Approved "CAB009861: AB_2180141" "unprognostic (1.57e-1)" "unprognostic (4.76e-2)" "unprognostic (2.22e-1)" "unprognostic (2.92e-2)" "unprognostic (1.79e-2)" "unprognostic (1.00e-1)" "unprognostic (2.91e-3)" "unprognostic (4.08e-3)" "unprognostic (2.02e-2)" "unprognostic (1.13e-1)" "unprognostic (9.93e-2)" "unprognostic (1.34e-1)" "prognostic favourable (5.42e-6)" "unprognostic (6.94e-2)" "unprognostic (1.35e-1)" "unprognostic (2.55e-1)" "unprognostic (4.62e-2)" 8.6 32.4 8.1 6.0 9.8 12.2 12.0 29.8 17.0 7.6 6.1 4.8 11.9 2.7 7.5 6.7 14.8 5.4 8.1 6.7 8.7 4.2 11.2 23.1 10.0 5.9 7.8 7.0 8.9 11.8 11.8 10.3 4.1 10.0 5.4 3.5 9.1 7.8 12.0 34.6 64.8 6.2 7.8 11.0 7.7 5.5 11.2 9.3 1.5 11.1 9.9 8.8 8.9 10.3 0.8 0.4 0.3 0.0 3.7 16.9 2.6 0.0 0.3 1.2 0.0 1.6 0.8 0.4 0.6 0.7 0.5 0.6 0.8 0.2 0.0 0.2 1.6 0.2 2.8 1.2 1.0 1.3 2.4 0.0 0.1 1.3 0.6 0.0 0.1 3.7 0.3 1.5 0.0 5.4 0.1 34.3 2.3 0.1 0.3 0.0 0.9 0.5 0.0 1.1 0.5 1.1 0.2 0.9 2.1 0.1 0.2 0.0 0.0 0.0 0.1 4.8 2.1 1.9 0.0 19.7 27.2 0.1 8.1 0.0 0.5 0.1 0.0 0.0 14.7 0.0 16.9 0.8 11.1 9.9 0.0 0.1 3.5 7.4 0.3 3.7 0.0 0.4 9.3 2.6 8.1 9.8 29.8 17.0 8.7 4.2 7.8 7.0 10.0 9.3 RORB "NR1F2, ROR-BETA, RZRB" ENSG00000198963 "RAR related orphan receptor B" Q92753 9 74497365-74693177 "Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Sensory transduction, Transcription, Transcription regulation, Vision" "Activator, Developmental protein, DNA-binding, Receptor" "Disease mutation, Epilepsy" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "brain: 35.5;cervix, uterine: 20.8" "Cell line enhanced" "Detected in some" "HHSteC: 19.9;HSkMC: 10.9;MOLT-4: 5.6;SH-SY5Y: 11.7" "Group enriched" "Detected in some" 5 "glioma: 2.1;prostate cancer: 2.3" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "neutrophil: 1.8" "Low lineage specificity" "Detected in single" "Low region specificity" "Detected in many" "Low region specificity" "Detected in all" HPA008393 Uncertain Approved Nucleoplasm Nucleoplasm "HPA008393: AB_1079830" "unprognostic (6.89e-3)" "unprognostic (4.06e-3)" "unprognostic (1.38e-1)" "unprognostic (3.97e-1)" "unprognostic (1.34e-1)" "unprognostic (1.05e-3)" "unprognostic (1.28e-1)" "unprognostic (1.18e-2)" "unprognostic (1.07e-1)" "unprognostic (3.07e-1)" "unprognostic (3.52e-1)" "unprognostic (5.46e-2)" "unprognostic (8.81e-8)" "unprognostic (5.97e-3)" "unprognostic (2.17e-2)" "unprognostic (2.26e-2)" "unprognostic (4.00e-2)" 3.1 7.9 8.3 1.2 11.1 1.0 1.4 1.8 35.5 20.8 1.3 2.1 2.2 1.1 8.9 0.9 1.7 1.5 4.5 3.9 5.6 7.0 2.0 1.0 2.0 0.9 4.1 18.7 1.4 1.1 1.1 4.0 10.6 6.1 10.5 1.6 18.7 1.2 11.7 0.9 1.3 1.1 1.7 6.7 1.0 1.6 2.0 3.7 2.2 1.5 0.0 1.5 2.3 2.2 0.2 0.2 1.8 0.2 0.6 0.6 0.0 0.0 0.0 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.3 0.0 0.0 0.0 0.0 19.9 0.0 0.6 10.9 0.0 0.0 0.0 0.0 0.0 3.1 0.0 0.1 5.6 0.0 0.8 0.6 0.0 0.0 0.0 0.0 0.0 0.2 11.7 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.4 0.0 0.9 0.0 0.0 0.0 0.4 2.7 0.0 1.3 0.2 0.2 0.1 0.1 0.1 0.1 0.1 0.1 0.0 0.2 0.1 0.6 1.8 0.6 0.1 0.2 0.0 0.0 8.3 11.1 1.8 35.5 5.6 7.0 4.1 18.7 6.1 3.7 RORC "NR1F3, RORG, RZRG, TOR" ENSG00000143365 "RAR related orphan receptor C" P51449 1 151806071-151831872 "Disease related genes, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Biological rhythms, Transcription, Transcription regulation" "Activator, Developmental protein, DNA-binding, Receptor" "Disease mutation" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "lymphoid tissue: 69.8;skeletal muscle: 63.8" "Cell line enhanced" "Detected in some" "HDLM-2: 21.1;Karpas-707: 11.0;MOLT-4: 5.6;RPMI-8226: 5.8;SK-BR-3: 5.0;T-47d: 8.9" "Low cancer specificity" "Detected in many" "Group enriched" "Detected in some" 4 "cerebellum: 7.0;pons and medulla: 2.4" "Cell type enriched" "Detected in some" 6 "MAIT T-cell: 28.3" "Lineage enriched" "Detected in single" 44 "T-cells: 28.3" "Low region specificity" "Detected in some" "Low region specificity" "Detected in all" HPA065620 Supported "Nuclear bodies" "Nuclear bodies" "HPA065620: " "unprognostic (6.51e-2)" "unprognostic (7.78e-2)" "prognostic favourable (1.83e-4)" "unprognostic (9.20e-2)" "unprognostic (3.05e-4)" "unprognostic (6.29e-5)" "unprognostic (1.13e-3)" "unprognostic (8.94e-2)" "unprognostic (1.67e-1)" "unprognostic (7.88e-2)" "unprognostic (3.78e-2)" "unprognostic (2.42e-1)" "prognostic favourable (2.94e-5)" "unprognostic (2.13e-1)" "unprognostic (3.22e-1)" "unprognostic (1.82e-2)" "unprognostic (1.80e-2)" 1.3 1.6 0.4 3.4 0.9 0.0 3.3 7.0 0.3 2.7 10.0 0.7 19.8 4.2 1.2 6.7 3.4 8.7 3.5 4.8 0.4 0.5 13.3 30.8 8.7 0.7 0.9 0.3 1.3 30.3 8.5 9.4 0.2 2.4 7.0 4.0 2.8 27.8 33.4 63.8 9.8 10.3 0.8 0.3 0.7 7.7 6.4 1.1 69.8 15.6 11.1 4.0 2.4 1.7 0.0 0.1 0.0 0.0 0.6 28.3 0.6 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 1.2 0.0 0.0 0.0 0.0 0.0 21.1 0.0 0.0 2.0 2.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 11.0 0.0 0.1 5.6 0.0 0.0 0.0 0.0 0.0 5.8 0.3 0.0 0.0 0.2 0.1 5.0 0.0 8.9 0.0 0.0 0.0 0.1 0.1 0.0 0.0 0.1 0.0 0.1 0.1 0.0 0.0 0.0 0.0 1.9 0.0 28.3 0.0 4.4 4.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.1 3.0 0.6 0.4 0.9 7.0 0.3 0.4 0.5 0.9 0.3 2.4 1.1 RXRA NR2B1 ENSG00000186350 "Retinoid X receptor alpha" P19793 9 134317098-134440585 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Host-virus interaction, Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "HaCaT: 27.0" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in many" "neutrophil: 14.9;non-classical monocyte: 12.3" "Group enriched" "Detected in many" 8 "granulocytes: 14.9;monocytes: 12.3" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB004565, CAB005352" Supported Supported "Nucleoplasm,Golgi apparatus" Nucleoplasm "Golgi apparatus" "CAB004565: AB_2184877, CAB005352: AB_2184874" "unprognostic (2.68e-1)" "unprognostic (7.94e-2)" "unprognostic (3.67e-2)" "unprognostic (7.22e-2)" "unprognostic (2.07e-2)" "unprognostic (6.69e-2)" "unprognostic (1.52e-1)" "unprognostic (2.15e-1)" "unprognostic (3.45e-2)" "unprognostic (1.65e-3)" "prognostic favourable (7.02e-4)" "unprognostic (7.72e-2)" "prognostic unfavourable (5.58e-4)" "unprognostic (1.25e-2)" "unprognostic (2.58e-1)" "unprognostic (1.49e-2)" "unprognostic (2.59e-1)" 18.5 10.1 9.9 10.4 6.7 19.6 36.8 4.6 9.8 11.0 9.3 4.9 8.1 14.0 10.1 6.1 24.2 9.3 12.9 14.2 9.0 3.7 11.7 49.3 12.8 10.4 6.0 7.0 11.7 20.6 8.0 10.7 9.6 9.4 9.7 2.0 9.5 9.3 9.7 45.8 19.0 15.2 10.6 9.5 11.5 8.8 5.9 8.1 1.5 13.6 18.3 5.9 16.0 23.7 0.1 1.7 14.9 12.3 1.3 1.1 1.8 5.5 15.6 2.0 5.0 3.5 3.3 24.0 3.0 3.5 4.3 2.5 8.6 8.7 0.0 8.2 4.3 27.0 0.7 10.6 0.2 7.9 2.0 0.0 19.0 13.1 4.5 6.5 2.4 5.3 4.5 5.4 2.5 3.7 10.7 0.5 1.0 14.9 0.5 1.4 3.8 5.4 2.8 7.4 10.8 0.2 24.1 4.4 2.0 9.5 9.1 2.4 12.6 8.9 4.8 5.3 6.4 5.7 2.6 0.7 0.0 0.1 4.0 6.6 3.4 1.1 5.2 2.8 1.1 9.3 0.0 0.1 0.7 0.7 1.7 0.0 0.2 0.9 14.9 1.3 12.3 0.1 0.9 1.8 9.9 6.7 4.6 9.8 9.0 3.7 6.0 7.0 9.4 8.1 RXRB "H-2RIIBP, NR2B2, RCoR-1" ENSG00000204231 "Retinoid X receptor beta" P28702 6 33193588-33200688 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in some" "CACO-2: 7.0;RH-30: 8.7;RT4: 8.2;T-47d: 8.5;U-698: 8.4" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in all" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002003, HPA063653" Supported Supported Nucleoplasm Nucleoplasm "CAB002003: , HPA063653: " "unprognostic (3.51e-1)" "unprognostic (8.46e-2)" "unprognostic (1.94e-1)" "unprognostic (2.22e-2)" "unprognostic (2.00e-2)" "unprognostic (4.71e-3)" "unprognostic (4.18e-2)" "unprognostic (2.21e-2)" "unprognostic (1.86e-1)" "unprognostic (2.03e-1)" "unprognostic (1.67e-3)" "unprognostic (8.13e-3)" "unprognostic (9.53e-3)" "unprognostic (8.30e-2)" "unprognostic (1.55e-1)" "unprognostic (6.38e-2)" "unprognostic (8.53e-3)" 24.9 18.9 13.0 14.0 16.1 9.8 16.0 24.7 23.2 22.8 17.1 17.7 17.3 19.0 17.4 56.6 13.7 18.5 17.1 27.7 13.5 12.3 14.1 17.4 16.5 9.8 16.4 15.6 19.1 16.2 3.6 17.5 19.2 15.5 20.1 8.4 16.0 16.2 22.0 19.7 25.5 14.1 28.4 10.4 19.8 13.9 10.4 18.2 18.5 22.0 10.9 24.5 14.0 14.5 1.9 1.4 5.2 1.2 1.9 2.5 0.7 0.0 0.0 0.0 0.0 0.0 0.0 4.4 0.0 0.0 0.0 0.0 7.0 0.0 5.3 4.0 0.0 3.5 0.0 0.3 0.0 0.0 0.0 0.0 0.0 0.0 5.1 0.0 5.8 0.0 0.0 0.0 0.0 0.0 5.2 0.0 5.2 0.0 0.0 0.2 3.1 0.0 0.0 8.7 0.0 5.3 8.2 0.0 4.7 0.0 0.0 0.0 8.5 0.0 0.0 0.0 3.8 0.0 0.0 6.8 5.8 8.4 0.0 0.0 0.0 5.2 0.8 2.9 2.5 0.9 1.8 1.9 2.5 2.4 1.3 0.8 2.4 1.5 1.9 1.9 1.2 1.4 2.5 0.7 13.0 16.1 24.7 23.2 13.5 12.3 16.4 15.6 15.5 18.2 RXRG NR2B3 ENSG00000143171 "Retinoid X receptor gamma" P48443 1 165400917-165445355 "Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, FDA approved drug targets" "Evidence at protein level" "Evidence at transcript level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Group enriched" "Detected in many" 4 "brain: 14.9;pituitary gland: 29.8;retina: 13.5;skeletal muscle: 44.8" "Cell line enriched" "Detected in some" 7 "SK-MEL-30: 28.3" "Group enriched" "Detected in many" 13 "melanoma: 25.7;thyroid cancer: 34.8" "Low region specificity" "Detected in many" "Not detected" "Not detected" "Not detected" "Not detected" "Region enriched" "Detected in many" 5 "basal ganglia: 89.8" "Low region specificity" "Detected in all" "CAB002615, HPA012933" Uncertain Approved "Nucleoplasm,Nuclear bodies" "Nucleoplasm, Nuclear bodies" "CAB002615: , HPA012933: " "unprognostic (2.29e-1)" "unprognostic (1.08e-2)" "unprognostic (1.51e-1)" "unprognostic (1.66e-1)" "unprognostic (4.29e-2)" "unprognostic (6.19e-2)" "unprognostic (1.35e-1)" "unprognostic (1.05e-2)" "unprognostic (9.13e-2)" "unprognostic (6.86e-2)" "unprognostic (2.95e-2)" "unprognostic (5.41e-3)" "unprognostic (2.52e-2)" "unprognostic (6.12e-3)" "unprognostic (1.18e-1)" "prognostic favourable (9.40e-5)" "unprognostic (5.03e-2)" 1.9 3.9 5.4 1.0 14.9 0.6 1.0 0.3 5.9 4.0 2.5 5.3 0.6 1.3 1.8 1.3 1.7 3.6 1.2 5.8 7.5 8.9 0.7 0.8 3.4 0.8 4.1 4.3 1.7 2.7 0.8 29.8 1.3 14.1 1.1 2.7 13.5 1.9 2.1 44.8 2.9 2.0 1.8 8.9 1.0 1.1 1.5 5.4 0.0 1.1 2.5 0.6 1.2 1.2 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.6 0.0 0.0 0.4 0.0 0.0 0.0 1.3 0.0 0.0 0.0 28.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 3.8 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 5.4 14.9 0.3 5.9 7.5 8.9 4.1 4.3 14.1 5.4 THRA "AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3" ENSG00000126351 "Thyroid hormone receptor, alpha" P10827 17 40058290-40093867 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Congenital hypothyroidism, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in all" "brain: 90.7" "Cell line enhanced" "Detected in many" "ASC diff: 37.1" "Low cancer specificity" "Detected in all" "Low region specificity" "Detected in all" "Low cell type specificity" "Detected in many" "Low lineage specificity" "Detected in many" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "HPA009654, CAB023349" Approved Supported Cytosol Cytosol "CAB023349: AB_619577, HPA009654: AB_1854603" "unprognostic (2.75e-2)" "unprognostic (2.20e-1)" "unprognostic (6.64e-2)" "unprognostic (4.22e-2)" "unprognostic (8.78e-2)" "unprognostic (1.64e-1)" "unprognostic (3.41e-3)" "prognostic favourable (1.84e-4)" "unprognostic (1.47e-1)" "unprognostic (5.47e-2)" "unprognostic (7.85e-2)" "unprognostic (2.65e-2)" "prognostic favourable (6.05e-8)" "unprognostic (3.05e-1)" "unprognostic (1.35e-1)" "unprognostic (4.21e-1)" "unprognostic (1.88e-3)" 17.1 20.7 58.6 5.7 90.7 9.9 12.9 37.4 73.1 19.8 12.6 24.1 8.2 15.1 19.3 11.5 9.7 29.3 12.7 30.1 43.8 38.1 12.1 2.7 11.6 4.5 34.3 45.5 46.5 12.3 13.0 10.7 8.5 29.6 12.4 9.6 10.4 13.7 18.8 38.5 10.0 16.7 17.4 29.4 6.1 11.9 7.8 43.6 1.8 12.5 7.9 3.3 10.0 18.6 1.0 1.5 3.7 0.7 5.1 4.7 1.4 2.1 17.2 5.4 13.4 37.1 13.6 1.9 8.8 10.6 9.2 8.6 14.3 12.5 2.5 14.7 17.2 5.2 10.5 5.4 5.0 0.9 9.9 4.6 20.5 6.1 12.5 7.5 5.2 21.6 4.4 8.6 3.3 12.3 9.3 2.4 7.6 3.2 10.0 12.4 4.9 5.4 14.4 10.6 12.4 3.1 1.5 9.1 8.3 6.8 10.9 15.4 12.7 8.9 8.5 9.2 9.2 8.2 2.6 5.6 3.9 1.5 5.7 8.7 4.9 0.3 0.6 3.7 4.7 0.3 2.0 0.6 1.9 2.8 0.8 1.0 3.4 4.1 2.5 5.1 0.7 1.5 2.2 1.4 58.6 90.7 37.4 41.8 43.8 38.1 34.3 45.5 29.6 43.6 THRB "ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2" ENSG00000151090 "Thyroid hormone receptor beta" P10828 3 24117153-24495756 "Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Low tissue specificity" "Detected in all" "Cell line enhanced" "Detected in many" "K-562: 26.0;RT4: 19.3" "Low cancer specificity" "Detected in many" "Low region specificity" "Detected in all" "Cell type enhanced" "Detected in some" "basophil: 7.2;naive B-cell: 4.3" "Group enriched" "Detected in many" 11 "B-cells: 4.3;granulocytes: 7.2" "Low region specificity" "Detected in all" "Low region specificity" "Detected in all" "CAB002008, CAB002009, HPA061035" Approved Supported "Nuclear bodies" "Nuclear bodies" "CAB002008: , CAB002009: , HPA061035: " "unprognostic (1.82e-1)" "unprognostic (4.22e-1)" "unprognostic (2.83e-1)" "unprognostic (2.20e-6)" "unprognostic (3.37e-1)" "unprognostic (2.66e-2)" "unprognostic (1.93e-2)" "unprognostic (1.73e-1)" "unprognostic (5.78e-3)" "unprognostic (2.95e-2)" "unprognostic (4.43e-1)" "unprognostic (2.01e-2)" "prognostic favourable (9.46e-8)" "unprognostic (1.32e-3)" "unprognostic (6.75e-2)" "unprognostic (2.73e-2)" "unprognostic (3.34e-2)" 10.7 5.5 12.5 3.2 14.8 1.1 12.0 2.6 27.0 3.6 11.2 1.9 5.5 2.7 7.5 2.2 7.0 4.3 2.5 7.9 9.2 5.7 12.9 20.8 5.4 1.6 4.3 20.1 2.9 9.6 6.8 20.3 4.7 3.5 8.2 9.0 3.2 6.1 10.4 21.9 7.1 4.0 11.1 3.0 5.7 8.1 1.0 4.0 0.0 4.9 4.7 1.6 9.8 14.6 4.3 0.5 7.2 0.1 0.0 0.0 3.5 5.9 1.8 0.4 0.0 10.7 5.6 4.0 0.2 1.3 1.0 1.9 3.9 5.9 0.0 1.5 4.2 9.0 6.4 2.5 0.7 0.0 3.9 0.0 1.6 5.1 0.3 0.0 0.0 9.9 4.4 0.1 0.7 0.0 26.0 0.0 0.9 0.3 0.0 0.0 3.9 2.2 0.0 0.0 0.0 6.1 19.3 1.1 0.4 9.8 5.3 0.1 5.8 0.0 0.5 2.4 1.9 0.0 1.1 0.1 0.3 0.0 1.7 0.0 0.2 7.2 0.1 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.5 4.3 0.0 0.0 1.6 0.0 0.0 0.0 0.0 3.5 12.5 14.8 2.6 27.0 9.2 5.7 4.3 20.1 3.5 4.0 VDR "NR1I1, PPP1R163" ENSG00000111424 "Vitamin D receptor" P11473 12 47841537-47943048 "Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters" "Transcription, Transcription regulation" "DNA-binding, Receptor" "Disease mutation, FDA approved drug targets" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Evidence at protein level" "Tissue enhanced" "Detected in many" "intestine: 57.1;parathyroid gland: 45.8" "Cell line enhanced" "Detected in many" "HBEC3-KT: 22.7;HDLM-2: 32.0;U-937: 31.4" "Low cancer specificity" "Detected in all" "Not detected" "Not detected" "Group enriched" "Detected in many" 6 "classical monocyte: 3.7;eosinophil: 2.1;intermediate monocyte: 7.0;myeloid DC: 5.7;neutrophil: 7.5;non-classical monocyte: 6.9" "Group enriched" "Detected in many" 8 "dendritic cells: 5.7;granulocytes: 7.5;monocytes: 7.0" "Region enhanced" "Detected in single" "olfactory region: 2.5" "Low region specificity" "Detected in some" "CAB004617, HPA047740, HPA072102" Supported "Nucleoplasm,Intermediate filaments,Cytosol" Nucleoplasm "Intermediate filaments, Cytosol" "CAB004617: AB_628040, HPA047740: , HPA072102: " "unprognostic (1.11e-2)" "unprognostic (5.49e-2)" "unprognostic (1.01e-1)" "unprognostic (7.59e-3)" "unprognostic (3.33e-3)" "unprognostic (2.74e-2)" "unprognostic (4.78e-2)" "unprognostic (1.69e-1)" "unprognostic (1.40e-1)" "unprognostic (1.62e-1)" "unprognostic (5.53e-3)" "unprognostic (6.72e-2)" "prognostic favourable (4.89e-6)" "unprognostic (1.46e-1)" "unprognostic (8.76e-2)" "unprognostic (3.28e-1)" "unprognostic (3.82e-2)" 3.0 9.2 0.2 10.0 0.3 2.5 7.8 0.3 0.6 3.5 40.9 0.4 4.1 21.2 1.2 7.7 10.2 1.1 10.7 1.5 0.5 0.3 13.0 0.6 8.3 3.8 0.5 0.1 1.3 6.5 45.8 11.7 4.4 0.6 2.1 12.6 0.4 4.9 2.8 5.3 15.2 57.1 1.2 1.5 3.1 2.6 1.5 0.2 2.0 1.9 9.4 8.2 4.0 5.2 0.7 5.7 7.5 7.0 0.2 0.8 1.2 5.4 0.9 0.0 0.0 4.7 6.9 0.1 6.7 3.4 5.7 5.0 4.0 4.6 1.4 7.3 4.6 10.2 0.2 22.7 2.7 32.0 1.6 2.4 1.3 0.3 3.5 4.8 7.7 9.3 10.6 6.3 10.4 0.4 0.7 1.5 2.6 3.7 0.1 2.3 0.0 7.4 0.1 0.0 3.5 5.2 5.5 2.6 0.1 5.7 16.5 2.0 18.6 2.7 0.4 11.0 2.9 3.2 3.8 0.9 0.0 1.2 3.4 31.4 2.7 0.2 3.7 2.1 0.0 7.0 0.1 0.7 0.3 0.0 5.7 0.1 0.1 0.0 7.5 0.2 6.9 0.6 0.8 1.2 0.2 0.3 0.3 0.6 0.5 0.3 0.5 0.1 0.6 0.2